TREATMENT OF AIDS

GUIDELINES FOR THE USE OF

ANTIRETROVIRAL THERAPY

IN MALAWI

Third Edition: Final Version

April 2008

Ministry of Health, Malawi
FOREWORD TO THE THIRD EDITION

In 2004, Malawi developed and started to implement a 2-year scale up plan for antiretroviral therapy (ART) to HIV-infected patients who were eligible for treatment. In January 2004, about 3,000 – 4,000 patients were accessing ART in 9 public health facility sites around the country. At that time, there was no standardised treatment, and no standardised system of training, monitoring, evaluation and drug procurement. However, this was about to change. The publication and dissemination of the 2003 First Edition of the ARV Treatment Guidelines provided the core material to ensure that Malawi moved forward to deliver ART to large numbers of HIV-infected eligible patients using a public health structured approach.

The country has done well. By the end of 2007, there were 109 facilities in the public sector (central, district, mission, and defence force hospitals and clinics) and 45 in the private sector delivering ART using national systems, and 145,000 patients had been registered for therapy.

The Ministry of Health developed a 5-year ART scale up plan (2006-2010) which lays out the path of how to deliver ART to over 250,000 or more HIV-infected eligible patients by the end of 2010. This will be a challenging time, and all the time the drugs and the field of HIV-treatment are changing.

With these thoughts in mind, I welcome the 2008 Third Edition of the “Guidelines for Antiretroviral therapy in Malawi”. This has built on the first and second editions, but takes into account the experience developed in the country in the last 4 years as well as changes that have occurred in international recommendations. I thank all the people who have given their time in the writing committee, consultation groups and dissemination meetings, and who have worked together to ensure the successful completion of an excellent and useful booklet. What now remains is to distribute this booklet to all health care workers in the public and private sector, and to insist that health care workers read, understand, digest and adhere to the contents. If this can be done, then patients with AIDS in Malawi will be offered an excellent standard of care. They deserve no less.

Mr C Kang’ombe  
Principal Secretary for Health  
Ministry of Health
ACKNOWLEDGEMENTS FOR THE FIRST EDITION

The National AIDS Commission and the Ministry of Health and Population gratefully acknowledge the help and assistance of the Writing Committee, who under the chairmanship of Dr. Andrina Mwansambo, were responsible for the first draft. Members of the Writing Committee in alphabetical order are:-

Dr. Andrew Agabu
Dr. William Aldis
Dr. Frank Bell
Dr. Neena Bodasing
Mr. Matt Boxhall
Dr. Nicolas Durier
Dr. Stephen Graham
Prof Anthony Harries
Dr. Mina Hosseinipour
Dr. Volker Hoynck
Dr. Perry Jansen
Mr. Godfrey Kadewere
Dr. Athanase Kiromera
Dr. Peter Kazembe
Dr. Edwin Libamba
Mr. Simon Makombe
Prof Elizabeth Molyneux
Dr. Rex Mpazanje
Dr. Andrina Mwansambo
Dr. Charles Mwansambo
Dr. Florian Neuhann
Mrs. Mtemwa Nyangulu
Mr. Sam Phiri
Dr. Olga Ascurra de Teck
Dr. Roger Teck
Dr. Joep van Oosterhout
Dr. Ralph Weigel

The National AIDS Commission and Ministry of Health and Population also thank other stakeholders and partner organisations for their assistance and inputs: - ABC Clinic; Admarc; Blantyre Adventist Hospital; Centres for Disease Control, Atlanta; Chitawira Private Hospital; Christian Hospital Association of Malawi; College of Medicine; John Hopkins Project, Blantyre; Jonas Salk Foundation, USA; Kamuzu College of Nursing; Lingazi Clinic, Lilongwe; Malawi Defence Force; Malawi Human Rights Commission; Medical Council of Malawi; Medicins sans Frontieres (Luxembourg; France); Maternal and Child Health Services; Nurses and Midwives Council; Umoyo Network; UNAIDS; UNC Project, Lilongwe; WHO (Malawi, AFRO, Geneva).
ACKNOWLEDGEMENTS FOR THE SECOND EDITION

The Ministry of Health gratefully acknowledges the help and assistance of the Writing Committee, who under the chairmanship of Dr. Edwin Libamba, was responsible for the second edition. Members of the Writing Committee in alphabetical order are:-

Dr. Andrew Agabu National AIDS Commission
Dr. Chitsa Banda Malawi Defence Force
Dr. Frank Bell College of Medicine, Blantyre
Dr. Kevin Bezanson Dignitas International, Zomba
Dr. Chin-nam Bong Taiwan Medical Mission, Mzuzu
Mr. Matt Boxshall Lighthouse Clinic, Lilongwe
Ms Rose Dzimadzi Nursing Dept, Ministry of Health
Dr. Stephen Graham Wellcome Trust, Blantyre
Prof Anthony Harries Ministry of Health
Dr. Mina Hosseinipour University of North Carolina
Dr. Perry Jansen Partners in Hope, Lilongwe
Dr. Kebba Jobarteh Baylor College of Medicine, Lilongwe
Dr. Athanase Kiromera St Gabriel’s Mission Hospital
Dr. Peter Kazembe Baylor College of Medicine, Lilongwe
Dr. Eddie Limbambala WHO Country office, Malawi
Dr. Edwin Libamba Ministry of Health
Mr. Simon Makombe Ministry of Health
Dr. Moses Massaquoi MSF-Thyolo District
Mr. Kondwani Mkandawire Malawi Medical Council
Prof Elizabeth Molyneux College of Medicine
Dr. Andrina Mwansambo National AIDS Commission
Dr. Charles Mwansambo Ministry of Health
Dr. Bern-T Nyang’wa MSF-Chiradzulu District
Mr. Sam Phiri Lighthouse Clinic, Lilongwe
Dr. Fasineh Samura MSF-Belgium, Thyolo
Dr. Erik Schouten Ministry of Health
Dr. Joseph Yu Taiwan Medical Mission, Mzuzu
Dr. Joep van Oosterhout College of Medicine
Dr. Ralph Weigel Lighthouse Clinic, Lilongwe
Prof Ed Zijlstra College of Medicine
ACKNOWLEDGEMENTS FOR THE THIRD EDITION

The Ministry of Health gratefully acknowledges the help and assistance of the Writing Committee, who under the chairmanship of Dr. Kelita Kamoto, was responsible for the third edition.

Dr. Jane Bates  Ministry of Health
Dr. Chitsa Banda  Malawi Defence Force
Mr. Matt Boxshall  Lighthouse Clinic, Lilongwe
Dr. James Bunn  College of Medicine (Paediatrics)
Dr. Peggy Chibuye  Ministry of Health
Mr. Rhehab Chimzizi  National TB Programme, MOH
Dr. Miriam Chipimo  UNICEF
Dr. Grace Chiudzu  Ministry of Health
Ms Rose Dzimadzi  Director, Mzuzu Central Hospital
Mr Peter Ellis  Clinton Foundation
Mr. Michael Eliya  Ministry of Health
Prof Anthony Harries  Ministry of Health
Dr. Roland Hogenschurz  Ministry of Health
Dr. Mina Hosseinipour  University of North Carolina
Dr. Ibrahim Idana  National TB Programme, MOH
Dr. Andreas Jahn  Lighthouse Clinic, Lilongwe
Dr. Kebla Jobarteh  Partners in Health, Neno
Dr. Marion Kambwanji  Dignitas International, Zomba
Mr. Hans Katengeza  Ministry of Health
Dr. Felix Kauye  Ministry of Health
Dr. Athanase Kiromera  St Gabriel’s Mission Hospital
Dr. Peter Kazembe  Baylor College of Medicine, Lilongwe
Dr. Kelita Kamoto  Ministry of Health
Dr. Eddie Limbambala  WHO Country office, Malawi
Ms. Ellen Makawa  Lighthouse Clinic, Lilongwe
Mr. Simon Makombe  Ministry of Health
Dr. Moses Massaquoi  MSF-Thyolo District
Dr. Ian Matondo  Ministry of Health
Dr. Erik McCollum  Baylor College of Medicine, Lilongwe
Mr. Kondwani Mkandawire  Malawi Medical Council
Dr. Jessie Mlotha  Ministry of Health
Prof Elizabeth Molyneux  College of Medicine (Paediatrics)
Dr. Peter Moons  College of Medicine (Paediatrics)
Mr. Philip Moses  Ministry of Health
Dr. Joseph Msosa  Ministry of Health
Dr. Andrina Mwansambo  National AIDS Commission
Dr. Charles Mwansambo  Ministry of Health (Paediatrics)
Mr. Lucius Ngoma’Ngoma  Ministry of Health
Mr. Amon Nkhata  Ministry of Health
Ms. Mtemwa Nyangulu  Ministry of Health
Mr. Olesi Pasulani  MSF-Thyolo District
Dr. Sam Phiri  Lighthouse Clinic, Lilongwe
Prof Felix Salaniponi  National TB Programme, MOH
Dr. Erik Schouten  Ministry of Health
Dr. Joep van Oosterhout  College of Medicine
Mr. Reuben Wenda  Ministry of Health
Dr. Ralph Weigel  Lighthouse Clinic, Lilongwe
Prof Ed Zijlstra  College of Medicine
**LIST OF ABBREVIATIONS**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AIDS</td>
<td>Acquired immune deficiency syndrome</td>
</tr>
<tr>
<td>ABC</td>
<td>Abacavir (antiretroviral drug)</td>
</tr>
<tr>
<td>ART</td>
<td>Antiretroviral therapy</td>
</tr>
<tr>
<td>ARV</td>
<td>Antiretroviral</td>
</tr>
<tr>
<td>AZT</td>
<td>Zidovudine (antiretroviral drug)</td>
</tr>
<tr>
<td>CPT</td>
<td>Cotrimoxazole preventive therapy</td>
</tr>
<tr>
<td>CT</td>
<td>HIV counseling and testing</td>
</tr>
<tr>
<td>CTX</td>
<td>Cotrimoxazole (antibiotic)</td>
</tr>
<tr>
<td>ddI</td>
<td>Didanosine (antiretroviral drug)</td>
</tr>
<tr>
<td>d4T</td>
<td>Stavudine</td>
</tr>
<tr>
<td>E</td>
<td>Ethambutol (anti-TB drug)</td>
</tr>
<tr>
<td>EFV</td>
<td>Efavirenz (antiretroviral drug)</td>
</tr>
<tr>
<td>EH</td>
<td>Ethambutol and isoniazid (anti-TB drugs)</td>
</tr>
<tr>
<td>ERT</td>
<td>Empowered reinforced therapy</td>
</tr>
<tr>
<td>GFATM</td>
<td>Global Fund to fight AIDS, tuberculosis and malaria</td>
</tr>
<tr>
<td>GST</td>
<td>Guardian supported therapy</td>
</tr>
<tr>
<td>HAART</td>
<td>Highly active antiretroviral therapy</td>
</tr>
<tr>
<td>HIV</td>
<td>Human immunodeficiency virus</td>
</tr>
<tr>
<td>HCW</td>
<td>Health care worker</td>
</tr>
<tr>
<td>IEC</td>
<td>Information, education and communication</td>
</tr>
<tr>
<td>“Kaletra”</td>
<td>Trade name for Lopinavir/Ritonavir (antiretroviral drug)</td>
</tr>
<tr>
<td>KS</td>
<td>Kaposi’s Sarcoma</td>
</tr>
<tr>
<td>LPV/r</td>
<td>Lopinavir/Ritonavir (antiretroviral drug)</td>
</tr>
<tr>
<td>MOH</td>
<td>Ministry of Health</td>
</tr>
<tr>
<td>MUAC</td>
<td>Mid-arm upper circumference</td>
</tr>
<tr>
<td>NNRTI</td>
<td>Non-nucleoside reverse transcriptase inhibitor</td>
</tr>
<tr>
<td>NRTI</td>
<td>Nucleoside reverse transcriptase inhibitor</td>
</tr>
<tr>
<td>NVP</td>
<td>Nevirapine (antiretroviral drug)</td>
</tr>
<tr>
<td>PEP</td>
<td>Post-exposure prophylaxis</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase chain reaction</td>
</tr>
<tr>
<td>PMTCT</td>
<td>Prevention of mother to child transmission (of HIV)</td>
</tr>
<tr>
<td>PTB</td>
<td>Pulmonary Tuberculosis</td>
</tr>
<tr>
<td>RHZ</td>
<td>Rifampicin, isoniazid and pyrazinamide (anti-TB drugs)</td>
</tr>
<tr>
<td>STI</td>
<td>Sexually transmitted infection</td>
</tr>
<tr>
<td>3TC</td>
<td>Lamivudine (antiretroviral drug)</td>
</tr>
<tr>
<td>TB</td>
<td>Tuberculosis</td>
</tr>
<tr>
<td>TDF</td>
<td>Tenofovir (antiretroviral drug)</td>
</tr>
<tr>
<td>TLC</td>
<td>Total lymphocyte count</td>
</tr>
<tr>
<td>UNAIDS</td>
<td>United Nations Consortium for AIDS</td>
</tr>
<tr>
<td>VCT</td>
<td>Voluntary counseling and HIV testing</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>TABLE OF CONTENTS</td>
<td>Page number</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Summary</td>
<td>7</td>
</tr>
<tr>
<td>Introduction</td>
<td>8</td>
</tr>
<tr>
<td>Framework for Antiretroviral delivery</td>
<td>11</td>
</tr>
<tr>
<td>The HIV-Antiretroviral Clinic and staffing</td>
<td>14</td>
</tr>
<tr>
<td>WHO Clinical staging of adults and children</td>
<td>17</td>
</tr>
<tr>
<td>Measurement of CD4 lymphocyte counts</td>
<td>21</td>
</tr>
<tr>
<td>Patients eligible for ART</td>
<td>22</td>
</tr>
<tr>
<td>Antiretroviral drugs: general principles</td>
<td>25</td>
</tr>
<tr>
<td>Standardised Treatment for Malawi: Principles</td>
<td>28</td>
</tr>
<tr>
<td>Implementing standardised ART in adults</td>
<td>32</td>
</tr>
<tr>
<td>Implementing standardised ART in children</td>
<td>35</td>
</tr>
<tr>
<td>Cotrimoxazole Preventive therapy with ART</td>
<td>36</td>
</tr>
<tr>
<td>Education for the patient and general public</td>
<td>37</td>
</tr>
<tr>
<td>ART in Special Situations</td>
<td>39</td>
</tr>
<tr>
<td>Women of childbearing potential and who are pregnant</td>
<td>39</td>
</tr>
<tr>
<td>Patients with liver disease</td>
<td>39</td>
</tr>
<tr>
<td>Patients with renal failure</td>
<td>39</td>
</tr>
<tr>
<td>Treatment of HIV-positive patients with tuberculosis</td>
<td>40</td>
</tr>
<tr>
<td>Treatment of HIV-positive patients with malignancy</td>
<td>44</td>
</tr>
<tr>
<td>Management of occupational and accidental exposure</td>
<td>45</td>
</tr>
<tr>
<td>Management of HIV exposure through rape</td>
<td>47</td>
</tr>
<tr>
<td>Monitoring ART</td>
<td>48</td>
</tr>
<tr>
<td>Registration of patients on ART</td>
<td>48</td>
</tr>
<tr>
<td>Monitoring and recording the treatment response</td>
<td>49</td>
</tr>
<tr>
<td>Adherence to ART</td>
<td>54</td>
</tr>
<tr>
<td>Monitoring and managing drug toxicity</td>
<td>55</td>
</tr>
<tr>
<td>Drug-drug interactions</td>
<td>60</td>
</tr>
<tr>
<td>Monitoring and managing immune reconstitution</td>
<td>61</td>
</tr>
<tr>
<td>Cohort analysis of treatment outcome</td>
<td>62</td>
</tr>
<tr>
<td>Surveillance for antiretroviral drug resistance</td>
<td>64</td>
</tr>
<tr>
<td>Supervision and national data collection</td>
<td>64</td>
</tr>
<tr>
<td>ARV Drug Supply and Use</td>
<td>65</td>
</tr>
<tr>
<td>Training in Use of ART</td>
<td>67</td>
</tr>
<tr>
<td>ART and Private Practitioners</td>
<td>67</td>
</tr>
<tr>
<td>Suggestions for further reading</td>
<td>68</td>
</tr>
<tr>
<td>Annexes (1 - 9)</td>
<td>69</td>
</tr>
<tr>
<td>Index</td>
<td></td>
</tr>
</tbody>
</table>
SUMMARY

Eligibility for ART:

Adult (aged 15 years and above):
Known to be HIV-seropositive and understand implications of ART
PLUS one of the following
i) Assessed to be in WHO Clinical Stage 3 or 4
ii) Have a CD4-lymphocyte count < 250/mm³
iii) Assessed to be in WHO Clinical Stage 2 with TLC < 1200/mm³

Children (aged 14 years and below):

Over the age of 18 months:
Known to be HIV-seropositive and relatives understand implications of ART
PLUS one of the following
i) Assessed to be in WHO Paediatric Clinical Stage 3 or 4
ii) Have a CD4-lymphocyte percentage < threshold (age-based- see table 11)
iii) Assessed to be in WHO Paediatric Stage 2 with TLC < threshold (table 11)

Under the age of 18 months:
Known to be HIV-seropositive and relatives understand implications of ART
PLUS one of the following
i) Assessed to be in WHO Paediatric Clinical Stage 4
ii) Have 2 or more of a) oral candida, b) severe pneumonia or c) severe sepsis

Under the age of 12 months where virological testing has been done:
All confirmed HIV-infected infants (confirmed by virological testing) irrespective of CD4-cell count or clinical stage

Antiretroviral Treatment Regimens:

First Line regimen:
Stavudine (d4T) + Lamivudine (3TC) + Nevirapine (NVP)
Formulation for children depends on body weight
Dose = one tablet in the morning and one tablet in the evening

Alternative first line regimen substitutions in case of drug reactions:
Reactions due to stavudine:
(severe peripheral neuropathy, pancreatitis, lactic acidosis)
Zidovudine (AZT) + Lamivudine (3TC) + Nevirapine (NVP)

Reactions due to nevirapine:
(severe skin reactions, hepatitis)
Stavudine (d4T) + Lamivudine (3TC) + Efavirenz (EFV)

Dual reactions to stavudine and nevirapine:
Zidovudine (AZT) + Lamivudine (3TC) + Efavirenz (EFV)

Second line regimen switch in case of failure to first-line regimen:
Adults: Zidovudine (AZT) + Lamivudine (3TC) + Tenofovir (TDF) + Lopinavir/ Ritonavir (LPV/r)

Children: Didanosine (ddI)+Abacavir (ABC)+ Lopinavir/Ritonavir (LPV/r)
INTRODUCTION

Global Burden of HIV/AIDS

At the end of 2007, 33.2 million adults and children were estimated to be living with HIV / AIDS in the world. Since the start of the epidemic in 1981, nearly 25 million people have died of AIDS. During the year 2007, it was estimated that there were 2.5 million people newly infected with HIV and there were 2.1 million AIDS deaths.

HIV/AIDS in sub-Saharan Africa and Malawi

Sub-Saharan Africa is the epicentre of this epidemic, with 22.5 million people living with HIV/AIDS by the end of 2007. 68% of all HIV-infections and 85% of all estimated AIDS deaths occur in this region. During 2007, there were 1.7 million new infections in the region and 1.6 million deaths. Of the 2.5 million children estimated to be living with HIV/AIDS globally, 2.2 million (88%) live in sub-Saharan Africa.

Malawi has one of the highest HIV/AIDS prevalence rates in the world, with 12.0% of those aged 15 – 49 years infected. These prevalence rates have remained stable for several years. Life expectancy has declined to 39 years from a projected 54 years without the HIV/AIDS epidemic. The National AIDS Commission estimated that in 2007 there were 898,888 adults and children living with HIV/AIDS and of these 89,025 were children aged less than 15 years. Of these, 100,000 HIV-infected adults and children were alive and on antiretroviral therapy by the end of 2007. HIV/AIDS is the leading cause of death in the most productive age group, resulting in 60,932 adult and child deaths annually. The cumulative number of orphans, directly related to the AIDS epidemic, is approximately 700,000 and more than 60,000 are added to this pool each year.

AIDS kills young adults in their most productive years, depriving the region of the skills and knowledge base so essential to human and economic development. AIDS thus leaves countless numbers of grandparents to bring up children. Many orphans cannot attend school. They may also suffer from poverty and malnutrition and become sucked into a spiral of crime, violence and commercial sex. AIDS retards development and creates the foundations for political instability. AIDS also causes high death rates in infected children, and 15% of under-5 deaths are directly attributable to HIV infection.

Combination antiretroviral therapy (ART)

Combination antiretroviral therapy (ART), previously known as highly active antiretroviral therapy or HAART has dramatically improved the survival of patients living with HIV and AIDS in industrialised countries of the world. AIDS has been transformed from a fatal disease into a potentially treatable and chronic condition. Access to ART is an important component of a strategy to support people living with HIV/AIDS as well as preventing transmission of infection. People are more willing to undergo HIV testing and counselling and disclose their HIV status when there is the possibility of getting effective treatment. By reducing viral load ARV drugs may, from a
biological viewpoint, reduce the risk of sexual transmission. Sick people will be able to return to work. Parents will stay alive longer, thus delaying the time when children become orphans. The rate of mother-to-child-transmission will be reduced.

**ART in Malawi – Progress to 2005**

In Malawi, it is estimated that 185,000 people are in immediate need of ART. At the beginning of 2004, there were 9 facilities in the public sector delivering ART, and an estimated 3,000 to 4,000 patients on treatment. As a result of this inadequate response, a major scale up of ART was planned. Between January and February 2004, the Ministry of Health, working alongside its partners, developed an ambitious and bold 2-year scale up plan for 2004 and 2005. The main elements of this plan were as follows:- i) 60 hospitals and clinics in the public health sector were selected for ART scale up, providing broad geographical coverage throughout Malawi; ii) ART drugs were provided free of charge in the public sector; iii) scale up in new facilities involved the use of the first line ART regimen only ( stavudine+lamivudine+nevirapine = “Triomune”), but when health facilities showed capacity to properly deliver such treatment they were to be provided with alternative first line and second line therapy; iv) facilities were only provided with ARV drugs if they had been formally assessed by the clinical HIV Unit of the Ministry of Health as ready to deliver ART therapy. It was agreed that ART must be provided within a structured framework, “a public health approach”. The first edition of the Malawi ARV Treatment Guidelines provided for such an approach, and the implementation of ARV delivery has been based on this document.

The Ministry of Health, the National AIDS Commission, other national stakeholders and donor institutions approved the scale up plan in February 2004. Implementation then started with an intensive period of briefings and trainings for clinicians and nurses in each of the 60 health facilities. The private sector was also brought on board, and by December 2005, 1350 clinicians and nurses in the public and private sectors had completed a formal ART training and passed the formal examination. In the latter half of 2004, the HIV Unit started structured assessments of all health facilities about readiness to start ART; by the end of March 2005, all the health facilities had been assessed as ready to start ART.

The procurement and distribution of ARV drugs was planned in a phased approach, with the 60 health facilities given a “quota” of drugs according to whether they were low burden (starting 25 new patients per month on therapy), medium burden (50 new patients per month) or high burden units (150 new patients per month). ARV drugs were procured according to “Starter pack kits and Continuation pack kits”, and these started to arrive in the latter half of 2004. By June 2005, all health facilities had received drugs and had started to treat patients.

A national monitoring system is in place and functioning. National and international stakeholders are kept briefed on progress by quarterly ART reports prepared by the HIV Unit. By the end of 2004, there were 13,183 patients who had ever started ART in the public sector in Malawi. By the end of 2005, this number had increased to 37,840. Of those ever started, 81% were alive and on ART by the end of December 2005.
ART in Malawi: 2006 – 2010

A five year plan (2006-2010) for ART scale up was developed and approved by the Ministry of Health and its stakeholders. Malawi’s “aspirational” goal will be to provide “Universal Access” of ART by 2010. Fulfilment of this goal means having 170,000 patients on treatment, and each year increasing this number by the number of patients becoming eligible for ART (i.e., 90,000 new patients per year). The goal of “Universal Access” is that adopted by the G8 countries in July 2005 and is the goal also adopted by the World Health Organization and UNAIDS.

However, the health sector works under considerable constraints in Malawi. The goal of “Universal Access” is ambitious and extremely demanding, and in reality cannot be reached, if Malawi wishes to run an ARV Programme, which is structured, organised and well monitored. On the road towards universal access, Malawi aims to have started 245,000 patients on ART by the end of 2010 and under the plan aims to achieve 50% or higher universal access. Based on the current successful “push” system of delivering ARV drugs and quotas given to hospitals, the table shows the estimated number of new patients starting ART per annum and the cumulative number of patients ever started on ART (and the number estimated to be alive) by the end of each year in the public and private sectors. There is a more explicit scale up of ART for children. By the end of 2005, children comprised 5% of all patients, but by 2010 it is envisaged that they will comprise 10% or more of new patients.

**Table: Targets of numbers started and alive on ART from 2006 - 2010**

<table>
<thead>
<tr>
<th>Year</th>
<th>Number of new patients –adults and children- registered on ART during the year (with number of new children shown in parenthesis)</th>
<th>Number of patients -adults and children- ever registered on ART by the end of the year (with number predicted to be alive by end of year)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>20,000 (1,000)</td>
<td>38,000 (30,000)</td>
</tr>
<tr>
<td>2006</td>
<td>35,000 (2,625)</td>
<td>70,000 (60,000)</td>
</tr>
<tr>
<td>2007</td>
<td>40,000 (4,000)</td>
<td>110,000 (90,000)</td>
</tr>
<tr>
<td>2008</td>
<td>45,000 (4,500)</td>
<td>155,000 (130,000)</td>
</tr>
<tr>
<td>2009</td>
<td>45,000 (4,500)</td>
<td>200,000 (170,000)</td>
</tr>
<tr>
<td>2010</td>
<td>45,000 (4,500)</td>
<td>245,000 (208,000)</td>
</tr>
</tbody>
</table>

The numbers of patients placed on ART will be achieved by expanding ART scale up and bringing on new sites on a year to year basis. Following Round 1 scale up with 60 ART sites, Round 2 scale up in 2006 brought on another 49 new sites and Round 3 scale up starts at the beginning of 2008 with another 54 sites (predominately 54 rural health centres) starting to deliver ART. Further rounds of scale up will follow. The private sector has also come fully on board, and by the end of 2007, 45 facilities were delivering ART. Plans to reduce the burden of work include less frequent follow-up of stable patients, decentralising the initiation and follow up of ART to health centres, and the use of task-shifting.

It is acknowledged that ART scale up must be accompanied by HIV prevention strategies, both for adults and for children (e.g., PMTCT), otherwise the country will have no chance of containing and coming to grips with the HIV/AIDS epidemic.
FRAMEWORK FOR ANTIRETROVIRAL DRUG DELIVERY

This framework lays out the public health approach for the wide scale delivery of antiretroviral (ARV) drugs. The framework consists of the following:-

- Goal
- Objectives and targets of ART
- Strategy for ART
- ART Policy Package
- Key operations involving ART
- Indicators to measure progress with ART

Goal

The goal is to reduce morbidity and mortality of HIV in adults and children.

Objectives and Targets

The principal objectives of antiretroviral drug delivery are:

- To provide long term ART to eligible patients
- To monitor and report treatment outcomes on a quarterly basis
- To attain individual drug adherence rates of 95% for patients on ART
- To increase life span so that at least 50% of patients on ART are alive and ambulatory after three years of ART
- To ensure that 80% of patients on ART are engaged in productive activity within 6 months of starting ART

Strategy

The strategy is to mobilise all existing ARV delivery sites and identify new ARV delivery sites to provide standardised combination ART to HIV-positive persons who present to health facilities and who fulfil the eligibility criteria (see Chapter on Patients Eligible for ART), using wherever possible guardian supported treatment.
ARV Policy Package

The success of the ARV delivery framework depends on the implementation of a 5-point policy package:

- government commitment to ART delivery
- detection of eligible cases (adults and children) who have undergone HIV testing and counselling, have a confirmed HIV-seropositive result and who fulfil eligibility criteria
- standardised combination ART to HIV-seropositive eligible patients (adults and children) under proper case management conditions with high levels of drug adherence
- regular, secure and uninterrupted supply of ARV drugs to units which are administering ART
- monitoring system for supervision of ART, effective patient tracing and follow-up and regular evaluation

Key Operations

- There is an HIV/AIDS Unit in the Ministry of Health, which has overall responsibility for the management of ART in the country
- The ARV treatment guidelines for adults and children are available in every treatment unit which administers ART, with these guidelines updated at regular intervals based on national experience and new international knowledge
- There is a standardised registration, recording and reporting system
- There is a combined training and examination programme, covering all aspects of ART delivery. All staff involved in ART delivery must have attended this training either as part of the undergraduate curriculum or part of in-service training, and must have passed the formal examination
- There is an HIV testing and counselling service linked to every unit providing ART, which is subject to regular quality assurance and quality control
- ART units are provided within the general health services, at hospital and also at health centre level
- There is a regular supply of ARV drugs and HIV testing materials
- There is a plan of supervision, mentorship, monitoring and evaluation
- There is a plan of regular reporting and evaluation
- HIV / AIDS research is fully regulated to support patient care and implementation of the ART guidelines
- There is a process to develop long-term and medium term plans with budget details, funding sources and responsibilities

Other important key operations essential to strengthen and sustain ART delivery include information, education, communication and social mobilisation, involving private and voluntary health care providers, and operational research.
Indicators and Targets to measure progress with ART delivery

**Input indicators:**

- An ART guideline manual (reflects government commitment)
- Number of districts providing ART (cumulative by year)
- Number of HIV-ART Clinics administering ART in public sector
- Number of HIV-ART Clinics administering ART in private sector
- Number of staff trained and accredited in use of ARV drugs in the public sector
- Number of staff trained and accredited in use of ARV drugs in the private sector
- No stock-outs of ARV drugs and uninterrupted supplies of ARV drugs to patients

**Output indicators:**

- The number of new patients (adults and children) registered on ART each year
- The number of patients (adults and children) who have ever registered on standardised ART
- The number of those registered on ART who are alive and taking therapy at any given time (i.e., under care): as part of an annual survey this will also include the number of children alive and taking therapy at any given time
- The number of patients alive and on ART according to first line, alternative first line and second line regimens
- The number (and proportion) of those starting ART who have died
- The number (and proportion) of those starting ART who have defaulted (i.e., have been lost to follow-up)
- The proportion of patients alive and on ART who are ambulatory
- The proportion of patients alive and on ART who are engaged in productive activities (or in the case of children engaged in age-related day time activities)
- The proportion of patients alive and on ART who show 95% adherence to ART
- In a sample of specimens assessed, the percentage of patients with undetectable viral load 12 months after the introduction of ART

The targets linked to these indicators are shown in [Annex 1](#). For further reading about goals, objectives and targets, please see the “5-year ART scale up Plan 2006-2010”.
THE HIV ANTIRETROVIRAL CLINIC AND STAFFING

Referral for HIV testing and counselling, and to the Antiretroviral Clinic

Referral for HIV testing and counselling can be from several sites such as the general outpatient departments of adult and paediatric medicine, the general adult and paediatric wards, the TB wards, the antenatal clinic, nutritional rehabilitation units, the laboratory and the community. Persons can also self-refer.

All persons who test HIV-positive at the HTC unit should be referred to the Antiretroviral Clinic for further assessment and staging: this also includes measurement of CD4-lymphocyte counts where appropriate (see Figure). Those who do not need ART will be referred to the general health services for management and advice, for example initiation of cotrimoxazole preventive therapy (CPT).

The Antiretroviral Clinic

ART will be provided to HIV-positive eligible patients. The clinics will be situated in hospitals (central, district, mission, and rural), health centres or other stand-alone sites. These guidelines do not advocate any rigid or specific design. Clinics must be set up and adapted to the context in which they are situated. However, there are a few key points which should be followed in setting up ARV clinics:-

- The Clinic should be physically integrated with the general out-patient services
- The Clinic must linked to HIV counselling and testing services, PMTCT services, the wards and out-patient departments
- The Clinic is specifically for HIV-positive patients, who need skilled care for the management of their opportunistic infections and malignancies and who need ART
- The Clinic will carry out the WHO Clinical Staging assessment in HIV-positive patients, as this staging determines whether or not the patient is eligible for ART. Where available, this assessment may be supplemented by CD4 count measurements.
- The Clinic needs space and possibly separate rooms for:-
  a) counselling, support and education of patients on ART
  b) clinical management of opportunistic infections, WHO clinical staging assessments, and clinical assessment of possible ART toxicity
  c) registration and initiation of ART and follow-up of patients on ART
- The Clinic will normally dispense ARV drugs, and in this way there will be a more robust accountability of drug usage. Patient visits will be planned and organised as discussed under Monitoring and Recording Treatment Response.
**Figure: Essential Steps in the referral to and screening at the HIV-Antiretroviral Clinic**

- **Referral sites:** Out-patients; Wards: PMTCT: Health centres

- HIV testing and counselling

- HIV-positive

- Screened for eligibility for ART:
  - eg WHO stage III or IV,
  - Low CD4-lymphocyte count or Low CD4%

- HIV-positive eligible for ART
  - Opportunistic infections stabilised

- Group counselling for ART

- Individual counselling for ART
  - Patient understands implications of ART

- **START ART**

- Linkage to support services, home based care
**HIV-Antiretroviral Clinic Staff for the public and private sector**

The health facility will determine the number and type of staff needed to run the ART Clinic. Trained ART staff should always be available for assessment and staging, and this can be done outside of the ART clinic. The ART clinic itself (in terms of initiating and following up patients on therapy) may run on five days a week, two days a week, or one day a week. Whenever it is being run, the minimum staff requirement is:-

- 1 clinician
- 1 nurse
- 1 ward clerk equivalent

Provided certain criteria are met (see below), medical officers, clinical officers, medical assistants and nurses can initiate and prescribe ARV drugs within these clinics, and all can provide follow-up of ART.

The criteria are that the staff have:- a) attended a pre-service ART training module and passed the final diploma or undergraduate examination, or b) attended an ART training course recognised by the Ministry of Health, Medical Council of Malawi and Nursing Council of Malawi and passed an examination based on this training course. Such health personnel will be certified as competent to manage ART. Details of the in-service certification mentioned under (b) are maintained in databases with the Medical Council of Malawi and Nursing Council of Malawi.

**Laboratory Back-up: minimum requirements**

An essential laboratory investigation is the HIV-antibody test. All HIV testing and counselling sites and laboratories attached to ART Clinics must be able to do quality-assured HIV-antibody tests. If zidovudine (AZT) is to be used, then the laboratory must also be able to carry out a Haemoglobin test.
WHO-CLINICAL STAGING OF ADULTS AND CHILDREN

The World Health Organization (WHO) staging system is for use where HIV infection has been confirmed through a positive HIV-antibody test or in the case of infants through a positive DNA-PCR test. The clinical stage is useful for a baseline assessment of a patient being considered for ART and also for follow-up. The clinical stages relate to survival, prognosis and progression of clinical disease without ART.

The table shows how symptoms relate to WHO Staging category.

**Table: WHO clinical staging of established HIV infection**

<table>
<thead>
<tr>
<th>HIV-associated symptoms</th>
<th>WHO Clinical Stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asymptomatic</td>
<td>1</td>
</tr>
<tr>
<td>Mild symptoms</td>
<td>2</td>
</tr>
<tr>
<td>Advanced symptoms</td>
<td>3</td>
</tr>
<tr>
<td>Severe/very advanced symptoms</td>
<td>4</td>
</tr>
</tbody>
</table>

**ADULTS AND ADOLESCENTS: (age range 15 years and above)**

The tables below provide the features in each Stage category for adults infected with HIV.

**Table: WHO Clinical Stage 1**

- Asymptomatic
- Persistent generalised lymphadenopathy

**Table: WHO Clinical Stage 2**

- Moderate unexplained weight loss
  (< 10% of presumed or measured body weight)
- Recurrent respiratory tract infections
  (sinusitis, tonsillitis, bronchitis, otitis media, pharyngitis)
- Herpes zoster
- Angular cheilitis
- Recurrent oral ulceration
- Papular itchy dermatitis
- Seborrhoeic dermatitis
- Fungal nail infections
### Table: WHO Clinical Stage 3

- Unexplained severe weight loss
  (> 10% of presumed or measured body weight)
- Unexplained chronic diarrhoea for longer than one month
- Unexplained persistent fever
  (intermittent or constant for longer than one month)
- Persistent oral candida
- Oral hairy leukoplakia
- Pulmonary tuberculosis (active or within the previous 2 years)
- Severe presumed bacterial infections (eg, pneumonia, empyema, pyomyositis, bone/joint infections, meningitis, sepsis)
- Acute necrotising ulcerative stomatitis, gingivitis or periodontitis
- Unexplained anaemia (<8g/dl), neutropenia (<500/mm³) or thrombocytopenia (<50,000/mm³)

### Table: WHO Clinical Stage 4

- HIV Wasting syndrome (unexplained severe weight loss >10% plus either chronic diarrhoea or fever in the absence of concurrent illness)
- Pneumocystis jiroveci (formerly: carinii) pneumonia [PCP]
- Recurrent severe or radiological presumed bacterial pneumonia
- Recurrent bacteraemia or sepsis
- Toxoplasmosis of the brain
- Cryptosporidiosis
- Isosporiasis
- Cryptococcosis, extrapulmonary
- Cytomegalovirus of an organ other than liver, spleen or lymph node
- Herpes simplex infection, mucocutaneous for > 1 month or visceral
- Progressive multifocal leucoencephalopathy
- Any disseminated endemic mycosis
- Candidiasis of oesophagus, trachea and bronchus
- Atypical mycobacteriosis, disseminated or lungs
- Extrapulmonary tuberculosis
- Lymphoma (cerebral or B cell non-Hodgkin)
- Invasive cervical carcinoma
- Kaposi’s sarcoma
- HIV encephalopathy
- Visceral Leishmaniasis
- symptomatic HIV associated nephropathy or cardiomyopathy
INFANTS AND CHILDREN (age range of less than 15 years):

The tables below provide the features in each Stage category for children with HIV.

**Table: WHO Paediatric Clinical Stage 1**

- Asymptomatic
- Persistent generalised lymphadenopathy

**Table: WHO Paediatric Clinical Stage 2**

- Unexplained persistent hepatomegaly and splenomegaly
- Papular itchy skin eruptions
- Extensive skin warts (human papilloma virus infection)
- Extensive molluscum contagiosum
- Recurrent oral ulcerations
- Unexplained persistent parotid gland enlargement
- Lineal gingival erythema
- Herpes zoster
- Recurrent or chronic respiratory tract infections
- (sinusitis, otorhhea, tonsillitis, otitis media)
- Fungal nail infections

**Table: WHO Paediatric Clinical Stage 3**

- Moderate unexplained malnutrition not responding to standard therapy
- Unexplained persistent diarrhoea for longer than 14 days
- Unexplained persistent fever above 37.5 (intermittent or constant for longer than one month)
- Persistent oral candida (outside the first 6-8 weeks of life)
- Oral hairy leukoplakia
- Acute necrotising ulcerative gingivitis or periodontitis
- TB lymphadenopathy
- Pulmonary tuberculosis
- Severe recurrent presumed bacterial pneumonia
- Symptomatic lymphoid interstitial pneumonitis
- Chronic HIV-associated lung disease, including bronchiectasis
- Unexplained anaemia (<8g/dl), neutropaenia (<500/mm³) or thrombocytopenia (<50,000/ mm³)
- HIV-associated heart or kidney disease

*a in general: defined by weight for height 70-79%; weight for age 70-79% (or below the third percentile in weight for age chart in health passport) on 2 measurements 3 months apart; weight loss >10% sustained over 3 months. in under 5s: defined as failure to gain weight over a period of 6 months. in children 1-5 years, defined as MUAC of 11-11.9cm. Simple anthropometric charts can be obtained from MOH, Nutrition Unit*
### Table: WHO Paediatric Clinical Stage 4

- Unexplained severe wasting, stunting, or severe malnutrition not responding to standard therapy \(^a\)
- Pneumocystis carinii (jeroveci) pneumonia
- Recurrent severe presumed bacterial infections (eg, empyema, pyomyositis, bone or joint infections, meningitis, sepsis, but excluding pneumonia)
- Toxoplasmosis of the brain
- Cryptosporidiosis with diarrhoea > 1 month
- Isosporiasis with diarrhoea > 1 month
- Cryptococcosis, extrapulmonary
- Cytomegalovirus of an organ other than liver, spleen or lymph node
- Chronic herpes simplex infection (orolabial or cutaneous for > 1 month) or visceral at any site
- Progressive multifocal leucoencephalopathy
- Any disseminated endemic mycosis
- Candidiasis of oesophagus, trachea and bronchus
- Atypical mycobacteriosis, disseminated or lungs
- Extrapulmonary tuberculosis, excluding TB lymphadenopathy
- Lymphoma (cerebral or B cell non-Hodgkin)
- Acquired HIV associated rectal fistula
- Kaposi’s sarcoma
- HIV encephalopathy

\(^a\) **in general**: defined by weight for height < 70%; weight for age <70%; bilateral oedema of both feet. **in children aged 1-5 years**: defined as MUAC of < 11 cm.

Simple anthropometric charts can be obtained from MOH, Nutrition Unit
MEASUREMENT OF CD4-LYMPHOCYTE COUNT

HIV infection causes a progressive decline in cell-mediated immunity. This is manifested by a decrease in the number of T-cell lymphocytes that bear the CD4 receptor, and these are known as CD4-lymphocytes. The immunological status of the HIV-infected infant, child, adolescent or adult can be assessed by measurement of the absolute number or % of CD4-lymphocytes, and this is regarded as the standard way to define the severity of HIV-related immunodeficiency.

Immunological status in adults and adolescents

Normal CD4 counts in adults and adolescents range from 500 – 1,500 cells per cubic millimetre of blood. HIV-associated immunodeficiency is advanced if the CD4 count is between 250- 349/mm³. HIV-associated immunodeficiency is severe or very advanced if the CD4 count is < 250/mm³.

Immunological status in children

The absolute CD4 counts and the percentage of CD4-lymphocytes in healthy infants, not infected with HIV, are much higher than those observed in uninfected adults, and slowly decline to adult values by 5 years of age. In considering absolute CD4 counts and CD4 percentages, age must therefore be taken into account. In children less than 5 years of age, the absolute CD4 count varies more than the CD4 percentage, and therefore measurement of CD4 percentage is more valuable in younger children. Not all equipment in Malawi is able to measure CD4 percentage, and measurements may have to rely on back calculation of the CD4% from an absolute CD4 count and the total lymphocyte count (from a full blood count).

In order to calculate the CD4%, a full blood count with differential white cell count and an absolute CD4 count must be obtained. To calculate a total lymphocyte count (TLC) a full blood count must be obtained. Below are the formulae used to calculate the TLC and CD4%:

\[ TLC = \text{absolute white blood cell count} \times \% \text{ lymphocytes} \]
\[ \text{CD4\%} = \frac{\text{absolute CD4 lymphocyte count}}{\text{total lymphocyte count (\%)}} \]

Example: The following are FBC and CD4 counts in a 2 year old infected child

**FBC**
- WBC: 9,000 cells/mm³
- Neutrophils: 60%
- Lymphocytes: 30%
- Eosinophils: 5%
- Monocytes: 5%

**CD4 count = 400 cells/mm³**

\[ \text{TLC} = 9,000 \, \text{cells/mm}^3 \times 0.30 = 2700/\text{mm}^3 \]
\[ \text{CD4\%} = \frac{400}{2700} = 0.14 = 14\% \]

This represents severe immuno-suppression in any child < 5 years of age. In a setting where CD4 counts are not available, this child is eligible for ART.
The proposed classification of immunodeficiency based on CD4-counts or CD4-percentages is shown in the Table below.

**Table: WHO proposed immunological classification of established HIV infection**

<table>
<thead>
<tr>
<th>HIV-Immune Deficiency</th>
<th>&lt; 1 year CD4%</th>
<th>1 yr to &lt; 3 yrs CD4%</th>
<th>3 yrs to &lt; 5 yrs CD4%</th>
<th>5 years and &gt; (per mm³)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not significant</td>
<td>&gt; 35</td>
<td>&gt; 30</td>
<td>&gt; 25</td>
<td>&gt; 500</td>
</tr>
<tr>
<td>Mild</td>
<td>30-35</td>
<td>25-30</td>
<td>20-25</td>
<td>350-499</td>
</tr>
<tr>
<td>Advanced</td>
<td>25-30</td>
<td>20-25</td>
<td>15-20</td>
<td>250-349</td>
</tr>
<tr>
<td>Severe</td>
<td>&lt; 25 (CD4&lt;1500)</td>
<td>&lt; 20 (CD4 &lt; 750)</td>
<td>&lt; 15 (CD4 &lt; 350)</td>
<td>&lt;250 (CD4 &lt; 250)</td>
</tr>
<tr>
<td></td>
<td>(TLC&lt;4000)</td>
<td>(TLC &lt;3000)</td>
<td>(TLC&lt;2500)</td>
<td>(TLC &lt;2000)</td>
</tr>
</tbody>
</table>

Patients with severe immunodeficiency are eligible for ART

**Priorities for CD4-lymphocyte count testing**

The **first priority** for CD4 count testing is to identify patients who are eligible for ART.

Priority for CD4 testing should go to:-

i) HIV-positive pregnant women identified through the PMTCT programme and who on clinical staging are not eligible for ART

ii) patients in WHO Stage 2

iii) HIV-infected children

The **second priority** for CD4 count testing is to support the identification of patients on ART who might have treatment failure. In these situations, CD4-lymphocyte counts should be measured at:-

i) Base-line

ii) Whenever failure on ART is suspected

The **third priority** is to do regular follow-up CD4 counts on a) patients already on ART and b) persons who are HIV-positive but are not yet eligible for treatment. This should only be done once the first and second priorities have been adequately covered:-

i) Follow-up every 6-12 months of patients on ART depending on capability of CD4-testing at the ART facility
ii) Follow-up every 12 months for people living with HIV with a CD4-count of $\geq 500$ cells/mm$^3$ and follow up every 6 months for people with a CD4 count of less than 500 cells/mm$^3$. 
PATIENTS ELIGIBLE FOR ART

ADULTS [persons aged 15 years and above]:

Asymptomatic patients who are HIV-positive are in general not eligible for ART because there is no evidence that early institution of ART benefits the patient. Adult patients will therefore be eligible for ART if they fulfil condition 1 and 2 PLUS either conditions 3, 4, 5 or 6:-

1. Patients are known to be HIV-seropositive

Patients must have undergone HIV testing and counselling, and must provide written evidence of a positive HIV-test result from a reputable and quality assured VCT counselling site.

Patients who provide verbal confirmation only of a positive HIV-test result are not eligible for ART.

2. Patients understand the implications of ART

Patients must have undergone counselling sessions (group and individual) during which the implications of ART have been discussed, in particular that ART requires high adherence and compliance and is a life long commitment.

Patients who are ill with an opportunistic infection or HIV-related malignancy should be treated appropriately and stabilised before considering the possible use of ART. ART is not an emergency treatment.

3. Patients are assessed as being in WHO Clinical Stage 3 regardless of CD4 lymphocyte count

Patients who have any of the features listed in Stage 3 (see the Table on page 18) should receive ART, but be stabilised before treatment commences.

There must be documented written evidence of a history of a) pulmonary tuberculosis within the past year or b) severe bacterial infections. Verbal reports of pulmonary TB or bacterial infections will not be acceptable as evidence for starting ART.

4. Patients are assessed as being in WHO Clinical Stage 4 regardless of CD4 lymphocyte count

Patients who have any of the features listed in Stage 4 (see the Table on page 18) should receive ART, but be stabilised before treatment commences.
5. Patients are assessed as being in WHO Clinical Stage 2 with a total lymphocyte count < 1200/mm³

A total lymphocyte count < 1200/mm³ in conjunction with clinical staging has useful prognostic significance. Therefore, patients with a low total lymphocyte count and any features in WHO Stage 2 (shown in the Table on page 17) are eligible for ART.

6. Patients have a CD4 lymphocyte below 250/mm³

Any patient HIV-seropositive with a CD4 count below 250/mm³ is eligible for ART regardless of WHO Staging or symptoms.

CHILDREN [persons aged 14 years or below]:

Asymptomatic children who are HIV-positive are in general not eligible for ART because there is no evidence that early institution of ART benefits the patient.

General Principles:

Although the pathogenesis of HIV and the underlying principles of antiretroviral therapy (ART) are similar in adults and children, there are specific physiologic, clinical, practical and social issues to consider when starting children on ART.

HIV progresses very rapidly in children infected through vertical transmission. Without intervention, almost 40% of vertically infected infants will die by 12 months of age, and over 50% will die by 24 months. Recent data has shown significant mortality benefit in starting children < 12 months of age on ART irrespective of CD4 count or clinical stage. Therefore, these guidelines recommend starting ART on all HIV-infected infants (<12 months of age) in whom the diagnosis of HIV has been confirmed.

The presence of trans-placental maternal antibody means that HIV infection cannot reliably be diagnosed using antibody-based HIV tests in children less than 18 months of age. Therefore, in such children, if available, a virological test called a DNA PCR is done to diagnose HIV infection. Blood samples for this test are collected on filter paper which is sent to a central lab for analysis.

A positive DNA PCR result indicates that the child is HIV positive.

A negative DNA PCR result needs to be interpreted with consideration as to whether the child has breast fed in the 6 weeks prior to the DNA PCR test. If the child has breast fed in the 6 weeks before testing then the child is defined as HIV exposed. This child needs to be retested with a DNA PCR 6 weeks after weaning from breast milk. If the child has not breast fed in the 6 weeks before testing then the child is HIV negative. This service is becoming more widely available in Malawi, and can be used to diagnose children as young as 6 weeks of age. All infants born to an HIV-infected mother should be tested by DNA PCR at 6 weeks of age.
If virologic testing is not available then all children born to HIV infected women must start CPT at 6 weeks of age.

HIV testing in children will be provided in the presence of a caregiver. However, older children and adolescents will need to be actively involved in HIV testing and counselling. The process of disclosure of the diagnosis to a child and an adolescent requires close co-operation with the caregiver and an experienced counsellor. Likewise, the implications of ART need to be explained to the caregiver and the child in an age-adapted fashion.

Paediatric patients will be eligible for ART if their care-givers have received appropriate counselling and understand the implications of ART and if they fulfil the age-related criteria set out below:

Children who are acutely unwell should be treated appropriately and stabilised before being considered for ART.

Normal lymphocyte counts and the proportion of lymphocytes expressing CD4 vary with age, particularly in young children. In children aged less than 5 years, the CD4 percentage is generally preferred as a measure of immune-status in HIV-infected children. However, from 5 years and above the absolute CD4 lymphocyte count can be used.

**Eligibility for ART in children over the age of 18 months**

Children over the age of 18 months will be eligible for ART if they are HIV-seropositive and they and/or their care givers understand the implication of ART, in the same way as for adults plus the following conditions shown below:-

- **WHO Paediatric Clinical Stage 4**
- **WHO Paediatric Clinical Stage 3**
- Children with a TLC, CD4 lymphocyte count or CD4 percentage below the threshold value for starting ART (see Table on page 21)

**Eligibility for ART in children under the age of 18 months**

For infants and children less than 18 months of age, the diagnosis of HIV infection is difficult because of the passage of maternal antibody. Virological testing is becoming more widely available in Malawi, but it has not yet reached all health facilities. In these situations, clinical criteria (shown below) can be used to for making the diagnosis of severe HIV disease requiring ART. Eligibility criteria then depend on a) no DNA-PCR available or b) a positive DNA-PCR test
Where no DNA-PCR test has been done:

The following are the criteria for eligibility for ART:-

- The infant is confirmed HIV antibody positive

and

- The infant is categorised in WHO Paediatric Clinical Stage 4 (this includes severe malnutrition)

or

- The infant is symptomatic with two or more of the following conditions:-
  i) oral candidiasis, ii) severe pneumonia and iii) severe sepsis

Other factors which support the diagnosis of severe HIV disease and ART eligibility in an HIV-seropositive infant include:- a) recent HIV-related maternal death, b) advanced HIV disease in the mother, and c) CD4 < 20% in children 12-18months, and <25% in children less than 12 months.

Where a DNA-PCR test has been done and is Positive:

The following are the criteria for eligibility for ART:-

- All HIV infected children with positive DNA-PCR < 12 months of age
  This is irrespective of clinical or immunologic status

- Any child > 12 months with WHO Paediatric Clinical Stage 4

- Any child > 12 months with WHO Paediatric Clinical Stage 3

- Any child > 12 months with CD4 or TLC counts below threshold values for starting ART (see table on p. 21)

These constitute the paediatric criteria for eligibility to ART. It is beyond the scope of this document to discuss social criteria for eligibility.
**ANTIRETROVIRAL DRUGS: GENERAL PRINCIPLES**

**Aims of Treatment**

The three main aims of ART are to:-
- Reduce HIV-related morbidity and mortality
- Prolong good quality life
- Assist the patient in being able to return to previous work or employment

**The Two Commonly Used Classes and their Drugs**

The commonly used antiretroviral drugs belong to two major classes:
1. Reverse Transcriptase Inhibitors (RTIs)
2. Protease Inhibitors (PIs)

Reverse transcriptase Inhibitors are further divided into 3 groups:
1. Nucleoside Reverse Transcriptase Inhibitors (NsRTIs)
2. Nucleotide Reverse Transcriptase Inhibitors (NtRTIs)
3. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Examples of antiretroviral drugs in each of these classes are shown in the Table.

**Table: Different classes of antiretroviral drugs, approved by WHO in 2006**

<table>
<thead>
<tr>
<th>NsRTI</th>
<th>NtRTI</th>
<th>NNRTI</th>
<th>PI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zidovudine  (ZDV)</td>
<td>Tenofovir (TDF)</td>
<td>Nevirapine (NVP)</td>
<td>Nelfinavir (NFV)</td>
</tr>
<tr>
<td>Didanosine  (ddI)</td>
<td></td>
<td>Efavirenz (EFZ)</td>
<td>Saquinavir (SQV)</td>
</tr>
<tr>
<td>Lamivudine  (3TC)</td>
<td></td>
<td>Delavirdine (DLV)</td>
<td>Ritonavir (RTV)</td>
</tr>
<tr>
<td>Stavudine   (d4T)</td>
<td></td>
<td></td>
<td>Lopinavir (LPV)</td>
</tr>
<tr>
<td>Zalcitabine (ddC)</td>
<td></td>
<td></td>
<td>Indinavir (IDV)</td>
</tr>
<tr>
<td>Abacavir    (ABC)</td>
<td></td>
<td></td>
<td>Amprenavir (APV)</td>
</tr>
<tr>
<td>Emtricitabine (FTC)</td>
<td></td>
<td></td>
<td>Tipranavir (TPV)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Atazanavir (ATV)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Darunavir (DNV)</td>
</tr>
</tbody>
</table>

[There are also several ritonavir-boosted PIs: eg lopinavir-ritonavir]

These drugs, used in combination, act by blocking the action of enzymes, which are important for replication and functioning of HIV.

Monotherapy (using one drug) is not recommended because of the inevitable development of drug resistance. However, for the specific indication of prevention of mother to child transmission of HIV infection, short course monotherapy may still be indicated.

Dual nucleoside therapy is also not recommended because it does not have a beneficial effect at a population level in terms of reducing HIV-related mortality and because dual therapy is also associated with rapid development of drug resistance. However, for post-exposure prophylaxis and for prevention of maternal to child transmission, short course dual therapy for 30 days is still indicated (see page 43).
Class-specific and drug-related side effects:

Class-specific side effects:

NsRTI  Mitochondrial toxicity
       Lipodystrophy syndrome with long usage
NtRTI  Renal toxicity
NNRTI  Skin rash
       Hepatitis
PI     Lipodystrophy syndrome
       Hyperlipidaemia
       Hyperglycaemia

Drug specific side effects:

Table: Some of the side effects of antiretroviral drugs

<table>
<thead>
<tr>
<th><strong>NsRTIs:</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Zidovudine</td>
<td>Anaemia, nausea, headache, fatigue, muscle pains, agranulocytosis</td>
</tr>
<tr>
<td>Didanosine</td>
<td>Nausea, diarrhoea, neuropathy, pancreatitis</td>
</tr>
<tr>
<td>Lamivudine</td>
<td>Nausea, headache, fatigue, muscle pains</td>
</tr>
<tr>
<td>Stavudine</td>
<td>Neuropathy, pancreatitis, diarrhoea, insomnia, lipodystrophy</td>
</tr>
<tr>
<td>Zalcitabine</td>
<td>Neuropathy, pancreatitis, oral ulcers</td>
</tr>
<tr>
<td>Abacavir</td>
<td>Nausea, fatigue, sleep disturbance, hypersensitivity reaction</td>
</tr>
<tr>
<td>Emtricitabine</td>
<td>Nausea, headache</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>NtRTI:</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tenofovir</td>
<td>Renal failure, osteoporosis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>NNRTIs:</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Nevirapine</td>
<td>Skin rash, Stephen Johnson Syndrome, hepatitis</td>
</tr>
<tr>
<td>Efavirenz</td>
<td>Skin rash, central nervous system disorders, teratogenicity</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>PIs:</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Nelfinavir</td>
<td>Diarrhoea, nausea, skin rash</td>
</tr>
<tr>
<td>Saquinavir</td>
<td>Diarrhoea, nausea, headache</td>
</tr>
<tr>
<td>Lopinavir/ritonavir</td>
<td>Diarrhoea, nausea, headache, abnormal taste, peri-oral numbness, pancreatitis</td>
</tr>
<tr>
<td>Indinavir</td>
<td>Nephrolithiasis, diarrhoea, nausea, abdominal pain, headache</td>
</tr>
<tr>
<td>Amprenavir</td>
<td>Diarrhoea, nausea, abnormal taste, peri-oral numbness</td>
</tr>
<tr>
<td>Tipranavir</td>
<td>Diarrhoes, nausea, abdominal pain, rash</td>
</tr>
<tr>
<td>Atazanavir</td>
<td>Diarrhoea, nausea, jaundice (due to indirect hyperbilirubinemia)</td>
</tr>
</tbody>
</table>
Drug Doses

Table: Standard adult doses of antiretroviral drugs

<table>
<thead>
<tr>
<th>Drug class / drug</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NsRTIs:</strong></td>
<td></td>
</tr>
<tr>
<td>Zidovudine</td>
<td>300 mg twice daily</td>
</tr>
<tr>
<td>Didanosine</td>
<td>400 mg once daily (250 mg once daily if &lt; 60Kg)</td>
</tr>
<tr>
<td>Lamivudine</td>
<td>150 mg twice daily</td>
</tr>
<tr>
<td>Stavudine</td>
<td>30 mg twice daily (weight in adults is no longer an issue)</td>
</tr>
<tr>
<td>Zalcitabine</td>
<td>0.75 mg three times daily</td>
</tr>
<tr>
<td>Abacavir</td>
<td>300 mg twice daily</td>
</tr>
<tr>
<td>Emtricitabine</td>
<td>200 mg once daily</td>
</tr>
<tr>
<td><strong>NtRTI:</strong></td>
<td></td>
</tr>
<tr>
<td>Tenofovir</td>
<td>300 mg once daily</td>
</tr>
<tr>
<td><strong>NNRTIs:</strong></td>
<td></td>
</tr>
<tr>
<td>Nevirapine</td>
<td>200 mg once daily for 14 days, then 200 mg twice daily</td>
</tr>
<tr>
<td>Efavirenz</td>
<td>600 mg once daily</td>
</tr>
<tr>
<td><strong>PIs:</strong></td>
<td></td>
</tr>
<tr>
<td>Nelfinavir</td>
<td>1250 mg twice daily</td>
</tr>
<tr>
<td>Saquinavir / ritonavir</td>
<td>1000 mg / 100 mg twice daily</td>
</tr>
<tr>
<td>Lopinavir / ritonavir</td>
<td>200 mg / 50 mg – two tablets twice daily</td>
</tr>
<tr>
<td>Indinavir / ritonavir</td>
<td>800 mg / 100 mg twice daily</td>
</tr>
<tr>
<td>Atazanavir</td>
<td>400 mg once daily</td>
</tr>
<tr>
<td>Atazanavir/ritonavir</td>
<td>300 mg/ 100 mg once daily</td>
</tr>
</tbody>
</table>

Novel classes of ARV drugs, which may become available in Malawi in the future

- Integrase inhibitors (e.g. raltegravir), which work on blocking the integrase enzyme and preventing HIV-DNA from inserting into the nucleus of the host cell

- Cell attachment inhibitors, which work by preventing the HIV from attaching to the cell.

- CCR5 co-receptor inhibitors (e.g. maraviroc), which work by preventing the HIV from binding to the important CCR5 co-receptor

- Fusion inhibitors, which work by preventing the HIV from fusing with the cell membrane and gaining entry to the cell cytoplasm. There is already an approved drug called “enfuvirtide or T-20”, currently given by injection.
STANDARDISED TREATMENT FOR MALAWI: PRINCIPLES

The First Line Regimen:

Basic principles for choosing the regimen:

The basic principles for choosing the first line regimen were:

• need for standardised therapy across the country
• ease of administration (e.g., once or twice a day)
• few side effects, especially side effect needing laboratory monitoring
• lack of interaction, where possible, with rifampicin
• previous experience with use
• price

Using these principles:

NsRTIs:
• zidovudine was not a good choice because of the tendency to cause anaemia, and therefore the need for haematological monitoring

NNRTIs:
• efavirenz was not a good choice because of the risk of teratogenicity

PIs:
• the whole class not a good choice because gastro-intestinal side effects are common, they all interact with rifampicin, they are expensive and are to be reserved for second line therapy

The choice of the first line regimen and the components:

Stavudine (d4T) + Lamivudine (3TC) + Nevirapine (NVP)

Stavudine (d4T)

This is a nucleoside reverse transcriptase inhibitor. It is easy to administer and generally well tolerated except in patients with peripheral neuropathy. Stavudine should not be combined with zidovudine (AZT) due to pharmacologic antagonism.

Side effects: the main immediate side effect is peripheral neuropathy: long term side effects include the lipodystrophy syndrome, lactic acidosis and other manifestations of mitochondrial dysfunction that also include peripheral neuropathy.

Stavudine is combined with Lamivudine as a dual therapy drug. Stavudine is combined with Lamivudine and Nevirapine as a triple therapy drug.
**Lamivudine (3TC)**

This is a nucleoside reverse transcriptase inhibitor. It is easy to administer and generally well tolerated. The drug should never be given as monotherapy as high grade resistance rapidly develops. The drug has useful activity against hepatitis B.

Side effects are infrequent, and mainly consist of headaches, nausea, diarrhoea, abdominal pain and insomnia.

Lamivudine is combined with Stavudine as a dual therapy drug.
Lamivudine is combined with Stavudine and Nevirapine as a triple therapy drug.

**Nevirapine (NVP)**

This is a non-nucleoside reverse transcriptase inhibitor. It is easy to administer. It has a long half life.

It is advisable not to give the drug as monotherapy as high-grade resistance rapidly develops. NVP is used as monotherapy for PMTCT. Nevirapine-based regimens may be used after the drug has been used as monotherapy for PMTCT.

There is a lead in dose for the first two weeks to reduce the frequency of skin rash. After the first two weeks the standard dose is administered.

There are two major side effects, which occur principally during the initial 8 weeks of treatment. The first major effect is a cutaneous hypersensitivity reaction (fever, rash, arthralgia and myalgia), which can lead to a life-threatening Stevens Johnson syndrome. The second major effect is drug-induced hepatitis. Women with a CD4 count > 250 and men with CD4 count > 400 may be at increased risk of hepatitis.

Nevirapine is combined with Stavudine and Lamivudine, as triple therapy.

**Interactions with other drugs:** Nevirapine induces cytochrome p450, and has some important drug interaction problems.

- There is an interaction with rifampicin, a drug which also induces cytochrome p450. Rifampicin decreases the levels of nevirapine by 30-40% and may therefore decrease its effectiveness and increase the risk of inducing NVP resistance (see section on TB and ART)

- There is an interaction with ketoconazole leading to a 30% increase in nevirapine levels and a 60% reduction in ketoconazole levels: the two drugs should not be used together.

- There is an interaction with oestradiol leading to a 20% decrease in effectiveness of oral contraception. Alternative or additional methods of contraception should be used.
Alternative First-line regimens to be substituted in case of drug reactions

Patients may experience adverse reactions to the first-line regimen (see Monitoring and Managing Drug Toxicity), and some of these may be serious enough to require stopping the first line regimen.

There are various adverse drug reactions requiring change of the first line regimen:-

**Reactions due to the Stavudine Component:**

These are in order of frequency:

i) Severe peripheral neuropathy

ii) Lactic acidosis / Lipodystrophy syndrome

iii) Pancreatitis

In these situations, the regimen is changed to

*zidovudine plus lamivudine plus nevirapine (AZT + 3TC + NVP)*

The patient will need regular monitoring every 3 months with measurements of Haemoglobin. Anaemia from AZT tends to occur within the first three months of treatment. Therefore consider Haemoglobin measurements at 1 month and then every 3 months after starting AZT or if there are clinical features suggesting anaemia.

**Reactions due to the Nevirapine Component:**

These are in order of frequency:

i) skin reactions

ii) hepatitis

In these situations, the regimen is changed to

*stavudine plus lamivudine plus efavirenz (d4T + 3TC + EFV)*

Women of child-bearing age will need to take precautions to avoid pregnancy because of the risk of teratogenicity of EFV. EFV may cross-react with nevirapine in being associated with skin reactions, and this drug may need to be introduced cautiously.

**Less common reactions:**

- reactions due to stavudine and nevirapine, change the regimen to
  *zidovudine plus lamivudine plus efavirenz (AZT + 3TC + EFV)*

- reactions due to stavudine and zidovudine (most commonly anaemia), change the regimen to
  *tenofovir plus lamivudine plus efavirenz (TDF + 3TC + EFV)*

- reactions due to nevirapine and efavirenz, change the regimen to
  *stavudine plus lamivudine plus lopinavir/ritonavir (AZT + 3TC + LPV/r)*
The Second line Regimen to be used in case of ART drug failure:

The second line regimen is used when patients have failed the first line regimen.

*ART Drug Failure:*

This is defined as i) the development of a new WHO Clinical Stage 4 feature, ii) a CD4 count / CD4% which has declined to pre-treatment values or less, iii) a CD4 count /CD4% which has declined to <50% of peak value on ART, iv) a CD4 count < 200 cells/mm³ after being on ART for more than 3 years. (persons need to fulfil one of i, ii or iii and fulfil iv; not: i, ii, iii, or iv) The CD4 measurements need to be confirmed one month later, and all events must have occurred in a patient who has been on ART for 6 months or more and adhering to therapy.

If the events above occur in a patient on ART, then the diagnosis of failure must be confirmed by a viral load test.

The decision to change to the second line regimen must therefore be made in consultation with a specialist at one of the central hospitals, where viral load tests can be done, because the regimen is more difficult for patients to take and requires more management.

*Replacement of d4T/3TC:*

*In Adults:*
Zidovudine + lamivudine + tenofovir will be the NRTI backbone to replace d4T and 3TC. AZT+3TC is a dual combination – If there is the K65R mutation then AZT retains some activity to this – If there is the M184 mutation from 3TC, then it is advantageous to maintain this mutation, as this mutated virus is poorly replicative and susceptible to other NRTIs. TDF is a useful NRTI and relatively easy to take

*In Children:*
In children abacavir and didanosine will be the NRTI backbone to replace d4T and 3TC. Unfortunately, there is little information regarding the use of tenofovir in children. Tenofovir causes decreased bone mineral density in children, and given the high rate of nutritional deficiencies in this population, this adverse effect counterbalances the benefits of using this potent drug. Zidovudine is also of concern for children because of the effects of AZT-induced anaemia.

*Replacement of NVP:*

Because of cross-resistance with other members of the NNRTI class, nevirapine has to be replaced with a protease inhibitor. The new heat stable tablet of Lopinavir/Ritonavir has now become available, removing the need to store the drugs in the fridge. Failure in Malawi will be diagnosed in a late stage, based mainly on clinical features, and thus there is a need for this powerful PI.
The regimens

In adults the following drug regimen is the chosen second line option:
Zidovudine (AZT) + Lamivudine (3TC) + Tenofovir (TDF) +
Lopinavir/Ritonavir (LPV/r)

In children the following drug regimen is the chosen second line option:
Didanosine (ddl) + Abacavir (ABC) + Lopinavir/Ritonavir (LPV/r)
[ddl in Malawi will be procured as enteric coated capsules, which can be taken with
food, in contrast to non-enteric coated tablets which are taken on an empty stomach]
IMPLEMENTING STANDARDISED ART IN ADULTS

First Line Regimen:

Introduction of the first line regimen for individual adult patients

- **Staging and management of HIV-related disease:** Eligible patients who are staged in the ARV Clinic will receive treatment and care for any HIV-related disease. The patient will be asked to choose a guardian to provide support for what will be life-long treatment. Both patient and guardian will return to the Clinic on another day to attend a formal group counselling session.

- **Group Counselling:** At the group counselling session, the patient and guardian will be educated about ART, using wherever possible a standard Flip Chart - the drugs, the importance of strict adherence to therapy, what to do in case of side effects, the importance of continuing to practice safe sex, the need to attend the clinic on the appointed dates and the responsibility of Clinic staff and facility support staff to follow-up the patient in the community in the event of “default” (see Chapter on Education). The patient, and if possible with the guardian, will be asked to return to the clinic in a few days to one week for individual counselling and start of ART.

- **Individual counselling and assessment of contraindications for ART:** The patient will be assessed for any contraindications to d4T/3TC/NVP. The main contraindications are obvious liver disease [jaundice] and renal failure. The understanding of the main messages from group counselling will be assessed and reinforced.

- **Weight and Height:** The patient will be weighed and have the height measured. This enables calculation of the body mass index (BMI) = wt in kg / ht in cm². All adults will now receive the stavudine-30mg regimen, which has been shown to be as effective as stavudine-40mg and with less toxicity.

- **Other blood tests:** If facilities permit, blood may be taken for full blood count, liver function tests and serum creatinine; however, these tests are not mandatory.

- **The first two weeks:** Patients will be given drugs for two weeks as follows:
  - **d4T/3TC/NVP 1 tablet morning plus d4T/3TC 1 tablet evening**
  The introduction of d4T/3TC/NVP in this fashion is because of the need to reduce the frequency of rash caused by nevirapine.

- **The two-week review:** Patients will be reviewed back at the treatment unit after two weeks. At that time, provided there are no side effects, patients will be given drugs for 30 days
  - **d4T/3TC/NVP 1 tablet morning plus 1 tablet evening**

- **Four-week reviews:** Patients will be seen every four weeks, and if there are no problems, will be prescribed drugs again for 30 days. If any side effects occur between reviews, patients must be told about the need to report to a health facility.
• Two-month reviews: After 6 months, if the patient is stable and doing well, the patient will be asked to attend a formal group counselling session on drug adherence after which clinic reviews can be every two months. If after one year, the patient is still stable, then consideration can be given to extending follow-up to three-monthly.

**Table: Steps in Administering First line ARV therapy**

<table>
<thead>
<tr>
<th>Steps</th>
<th>Medication Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>First two weeks</td>
<td>d4T/3TC/NVP 1 tablet in the morning</td>
</tr>
<tr>
<td></td>
<td>Plus</td>
</tr>
<tr>
<td></td>
<td>d4T / 3TC 1 tablet in the evening</td>
</tr>
<tr>
<td>Next month</td>
<td>d4T/3TC/NVP 1 tablet in the morning</td>
</tr>
<tr>
<td></td>
<td>Plus</td>
</tr>
<tr>
<td></td>
<td>d4T/3TC/NVP 1 tablet in the evening</td>
</tr>
<tr>
<td>Monthly reviews for first 6 months</td>
<td>d4T/3TC/NVP 1 tablet in the morning</td>
</tr>
<tr>
<td></td>
<td>Plus</td>
</tr>
<tr>
<td></td>
<td>d4T/3TC/NVP 1 tablet in the evening</td>
</tr>
<tr>
<td>2-monthly reviews after 6 months</td>
<td>d4T/3TC/NVP 1 tablet in the morning</td>
</tr>
<tr>
<td></td>
<td>Plus</td>
</tr>
<tr>
<td></td>
<td>d4T/3TC/NVP 1 tablet in the evening</td>
</tr>
</tbody>
</table>

**Alternative First-line regimens to be substituted in case of drug reactions**

*Change needed due to the Stavudine Component:*

This change will be because of severe peripheral neuropathy, pancreatitis or lactic acidosis. The patient is changed to

**zidovudine plus lamivudine plus nevirapine (AZT + 3TC + NVP)**

The dose of medication is:-

- AZT+3TC 1 tablet morning and 1 tablet evening
- NVP 1 tablet morning and 1 tablet evening

At the time of writing these guidelines, this medication is administered as a dual combination tablet of AZT and 3TC (one tablet in the morning and one tablet in the evening, from bottles of 60 tablets) and tablets of NVP (one tablet in the morning and one tablet in the evening, from bottles of 60 tablets). Thus, the patient takes 4 tablets a day.
Change needed due to the Nevirapine Component:

This change will be because of skin reactions or hepatitis. The patient is changed to:

stavudine plus lamivudine plus efavirenz (d4T + 3TC + EFV)

The dose of medication is: d4T+3TC 1 tablet morning and 1 tablet evening
EFV 1 tablet evening

At the time of writing these guidelines, this medication is administered as a dual combination tablet of d4T and 3TC (one tablet in the morning and one tablet in the evening, provided in bottles of 60 tablets) and one additional tablet of EFV (one tablet taken last thing at night to prevent neuro-psychiatric side effects, provided in bottles of 30 tablets).

Thus, the patient takes 3 tablets a day

This substitution is complicated by the fact that nevirapine has a long half life and the triple therapy drug should not be stopped completely at once, otherwise NVP drug resistance may be allowed to occur. The following steps are therefore recommended:

- Stop triple therapy drug
- Immediately start d4T and 3TC, one tablet twice a day, and continue for one week
- Then stop d4T and 3TC, and wait until the rash or hepatitis has settled
- Then start d4T and 3TC and EFV

The Second line Regimen:

The following drug regimen is the chosen second line option:

Zidovudine (AZT) + Lamivudine (3TC) + Tenofovir (TDF) + Lopinavir/Ritonavir (LPV/r)

The drugs are taken as: AZT+3TC one tablet morning and one tablet evening
TDF one tablet morning
LPV/r two tables twice a day, morning and evening

LPV/r and TDF can be taken independently from food.
IMPLEMENTING STANDARDISED ART IN CHILDREN

ART will be initiated at an HIV-Antiretroviral Clinic. This clinic will not replace regular services of under 5 clinics, and on-going attention should be paid to vaccinations, weight monitoring, diagnosis and treatment of opportunistic infections. Staff providing ART for children must have received appropriate training in the use of paediatric ART.

First line Regimen

Ideally, antiretroviral drugs for children should be available as paediatric formulations, i.e. palatable syrups for administration in appropriate volumes. However, liquid preparations present their own particular problems, including increased bulk and weight (for storage and transport), increased cost, limited shelf-life and the need for caregivers to measure volumes. There is currently no liquid combination formulation available for d4T/3TC/NVP, and although individual syrups are available for 3TC and NVP, d4T syrup needs to be kept refrigerated.

A new paediatric fixed dose combination of d4T 6mg/3TC 30mg/NVP 50mg (known as Triomune-Baby) should be used for children less than 10 kg (Annex 2a). Please note that the dosage table given in Annex 2a is in line with current WHO recommendations but different from the dosage table found in the package insert by the time of writing. Compared to the split adult T30 regimen in Annex 2b, the new formulation provides higher NVP concentrations (target NVP dose is 300mg/mm2/d); especially for children <10kg of body weight.

If the new formulation is unavailable children less than 10 kg should receive split adult T30 regimen as set out in Annex 2b.

Children 10 kg and above should generally receive split adult T30 regimen as set out in Annex 2b.

The initiation of treatment should follow the same general steps as shown earlier for adults. Treatment should be initiated with a single daily dose of d4T/3TC/NVP with once daily d4T/3TC given for the first two weeks. Caregivers should be asked to re-attend promptly if the child develops a rash or becomes unwell. Guardians should be instructed not to stop therapy without authorisation from clinic staff.

Alternative First-line regimens to be substituted in case of drug reactions

Children, like adults, may experience adverse reactions to the first-line regimen, and some of these may be serious enough to require stopping the first line regimen. The same recommendations, as for adults, apply to children. Doses and guides to starting alternative first line ART are given in Annex 3:

In children under 3 years of age, the triple combination with EFV cannot be recommended in view of lack of pharmacokinetic data before this age: in these
situations, the first line regimen is stopped, not substituted and specialist opinion must be sought.

**The Second line Regimen:**

Children may fail first line treatment. However, different recommendations about the regimen apply to children compared with adults. Doses and advice about starting second line ART are given in Annex 3. Specialist opinion must be sought.

**ART in children younger than 1 year of age**

The writing committee supports universal ART for DNA PCR confirmed HIV infected children younger than 1 year of age in line with current evidence of high mortality in this age group. However, operational research is being conducted to determine the best ART regimen for these children in Malawi in accordance with locally available resources and also taking into consideration the current PMTCT regime. Until more guidance is available, it is strongly recommended that a low threshold for ART treatment is practiced, especially in children not exposed to nevirapine prophylaxis

**COTRIMOXAZOLE PREVENTIVE THERAPY WITH ART**

There is a national policy on use of cotrimoxazole preventive therapy (CPT). The main indications for CPT are shown in the Table below

**Table: CPT is offered to the following adults and children who are known to be HIV-positive**

<table>
<thead>
<tr>
<th>Adults</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Any person with symptomatic HIV disease [Stages 2,3 and 4]</td>
<td></td>
</tr>
<tr>
<td>Any person who has a CD4 count of 500/mm³ or less, regardless of symptoms</td>
<td></td>
</tr>
<tr>
<td>Pregnant women after the first trimester</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Children</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Any child, aged 6 weeks or more, born to an HIV-positive woman irrespective of whether the woman received ART in pregnancy</td>
<td></td>
</tr>
<tr>
<td>Any child, 6 weeks or more, who is HIV-positive regardless of symptoms</td>
<td></td>
</tr>
</tbody>
</table>

CPT is also offered to DNA-PCR- negative children who continue to breast feed.

All patients eligible for ART are also eligible for CPT. Every attempt should be made to place such patients on CPT either before or at the same time as starting ART.
The dosages of CPT for tablets and for solutions for children are shown in the Tables below.

**Table: Dosages of CPT tablets**

<table>
<thead>
<tr>
<th>Category</th>
<th>Dosage of CPT (480mg tablets)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults</td>
<td>One tablet (480mg) twice a day</td>
</tr>
<tr>
<td>Children aged 5-14 years</td>
<td>One tablet (480mg) once a day</td>
</tr>
<tr>
<td>Children aged 6 months to 4 years</td>
<td>Half a tablet once a day (240mg daily)</td>
</tr>
<tr>
<td>Children aged 6 weeks to 5 months</td>
<td>Quarter of a tablet once a day (125 mg daily)</td>
</tr>
</tbody>
</table>

**Table: Dosages of CPT solutions for children**

<table>
<thead>
<tr>
<th>Age category</th>
<th>Dosage of CPT solution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Children aged 5-14 years</td>
<td>10ml once a day</td>
</tr>
<tr>
<td>Children aged 6 months to 4 years</td>
<td>5ml once a day</td>
</tr>
<tr>
<td>Children aged 6 weeks to 5 months</td>
<td>2.5ml once a day</td>
</tr>
</tbody>
</table>

**Contra-indications to CPT:**

Known allergy to cotrimoxazole for adults and children
First trimester of pregnancy for adult women

**Duration of therapy:**

**Adults:**

CPT should be lifelong. If antiretroviral therapy is started, then CPT should be continued. If CD4 counts are monitored on ART and the CD4 count rises above 500/mm³, then CPT may be discontinued. CPT should be **discontinued** in the event of severe cutaneous reactions, renal or hepatic toxicity or severe haematological toxicity. In these situations, dapsone can be considered as an alternative prophylaxis.

**Children:**

In HIV-exposed infants (ie children born to HIV-positive women) CPT should be taken until HIV infection can be confidently excluded. At 18 months of age and provided the child has stopped breast-feeding, the child should have an HIV test. If the child continues to breast feed after 18 months, CPT is continued until 3 months after breast-feeding has stopped and the child is then offered an HIV test. In both
situations, if the HIV test is positive, then the child continues on CPT indefinitely. If the HIV test is negative, then the child discontinues CPT.

HIV-positive children take CPT life-long. If antiretroviral therapy is started, then CPT should be continued. CPT should be **discontinued** in the event of severe cutaneous reactions, renal or hepatic toxicity or severe haematological toxicity

**Pregnant women on CPT:**

If a pregnant woman is on CPT, then there is no need for her to take intermittent antimalarial prophylaxis with sulfadoxine-pyrimethamine.
EDUCATION FOR THE PATIENT AND GENERAL PUBLIC

Education for the patient and the care giver/ guardian

Before patients start on ART they must understand the implications of therapy and be prepared to accept therapy as a life long commitment. Group counselling sessions must be conducted on HIV /AIDS with due reference to the benefits and dangers of ART followed by individual counselling sessions.

Counsellors and clinicians must be trained in providing key messages about ART, and regular counselling sessions should be a routine part of the service provided at the HIV Clinic. Staff at the HIV clinic should encourage HIV-positive patients who are on ART to enrol as "educators" and counsellors, for these patients can provide valuable information about ART to the patients who are starting therapy.

Patient education must occur at the start of ART and during therapy. It is recommended that 6 months after therapy, patients routinely attend a group counselling session, and if adherent and stable, these patients can be recommended for 2 monthly follow-up visits. Adherence counselling in groups should occur every 6 months.

IEC materials on ART, which have been distributed to health facilities and public places (e.g. ART patient calendars), must be used to educate patients and care givers. Radio broadcasts will also be a regular feature, so that patients and the general public are made aware of the benefits and dangers of ART.

Wherever possible, support groups, including national organizations such as NAPHAM, MANET and MANASO should be used to help patients and their caregivers in ensuring adherence to ART.

The key messages about ARV drugs and ART are:-

- The drugs are not a cure and have to be taken for life
- Patients remain infective and therefore need to practice safe sex and use condoms
- Only drugs prescribed from certified practitioners should be taken
- All the drugs have to be taken daily according to prescription advice, otherwise they will become ineffective because of resistance. Guardians and care givers must support drug administration for children
- Drugs must not be shared with relatives or friends
- If an adverse effect occurs while on the drugs, a clinician must be consulted. If the side effect is jaundice or a severe skin rash with blisters in the mouth or around the genitalia, the drugs must be stopped and a clinician seen as quickly as possible.
• In the event of not showing at the clinic, the ART clinic staff and the support services will try and trace the patient or the guardian to find out what has happened – the master card has a field that explicitly requests patient consent for defaulter tracing

• At every clinic visit, the patient or the guardian must bring back the pill container so that clinic staff can count the remaining number of pills in the container (see section on patient monitoring and drug adherence)

• If there is evidence that drugs are being sold in market places this must be reported to the health authorities in order for action to be taken - such practices will lead to the development of widespread resistance to ARV drugs

• ARV drugs in the first line regimen, alternative first line and second line regimens can be taken independently of food. It is important that patients try and get as good nutrition as possible (see Nutrition guidelines). It is best to avoid alcohol

• If the patient dies, the remaining ARV drugs must be returned to the ART Clinic. These drugs must then be destroyed in accordance with standard pharmaceutical practices

**Education for the general public**

Key messages for the general public are:-

• ARV drugs are not a cure for patients and have to be taken for life

• Patients remain infective and therefore need to practice safe sex and use condoms where appropriate

• Only drugs prescribed from certified practitioners should be taken

• All the drugs have to be taken according to the prescription advice, otherwise they will become ineffective because of resistance

• Drugs must not be shared with relatives or friends

• If a person is raped, then the nearest health facility must be approached as soon as possible regarding implementation of post-exposure prophylaxis
ART IN SPECIAL SITUATIONS

WOMEN OF CHILDBEARING POTENTIAL AND WHO ARE PREGNANT

ART is a priority for pregnant women who are eligible for ART, because triple therapy is very effective in reducing mother to child transmission of HIV. Wherever possible, HIV-positive pregnant women should have a CD4-lymphocyte count performed to determine eligibility for ART even in the absence of symptoms. In the event of waiting lists, HIV-positive eligible pregnant women should be given priority. HIV-positive women should also be started on CPT.

Nevirapine, one of the components of d4T/3TC/NVP, can lower the blood concentration of oral contraceptives, and additional or alternative contraceptive methods (such as medroxyprogesterone for women or condoms for men) should be considered to avoid pregnancy in women using these drugs. If efavirenz is used as an alternative first line drug, this is teratogenic: women who are taking efavirenz must take appropriate contraception to avoid getting pregnant.

d4T/3TC/NVP is not contraindicated in pregnancy, and can be safely given. Thus, if a woman becomes pregnant while on d4T/3TC/NVP, this can be continued.

Any woman who is taking triple ART and becomes pregnant should continue with the first line regimen, and not be given nevirapine at the onset of labour. However, the child born to such a woman should be given the standard recommended ARV prophylaxis within 72 hours of birth (see Second Edition of PMTCT Guidelines).

D4T/3TC/NVP can be given to lactating mothers and reduces the risk of HIV transmission during breastfeeding. Breastfeeding should be exclusive for the first 6 months according to the Second Edition of PMTCT Guidelines.

PATIENTS WITH LIVER DISEASE

Patients with acute hepatitis (manifested by jaundice) should not be given d4T/3TC/NVP. Patients with established stable chronic liver disease should be referred for specialist opinion about whether they can start ART.

PATIENTS WITH RENAL FAILURE

Both stavudine and lamivudine are eliminated by the renal route, and need dose reductions as renal failure progresses. NVP does not require dose adjustment in renal failure. Specialist advice is needed for the administration of ART in case of renal failure. As d4T/3TC/NVP cannot be reduced in relation to creatinine clearance individual drugs have to be given. This treatment might be considered at central hospital level, although the individual drugs will have to be obtained on a named patient basis. Renal failure will not automatically exclude patients from treatment, because patients with HIV nephropathy can directly benefit from ART.

TDF is also excreted through the renal route and may need dose adjustment in renal failure.
TREATMENT OF HIV-POSITIVE ADULTS AND CHILDREN WITH TUBERCULOSIS

Background:

Patients with tuberculosis are treated with standardised regimens in Malawi. All regimens include an Initial Phase of Treatment with 3 to 5 drugs, and a continuation phase usually with two drugs (see TB Treatment Manual, 2007, Edition 6). In the initial phase and continuation phase of treatment, all drug combinations include rifampicin, which interacts with nevirapine.

The problem: rifampicin and non-nucleoside reverse transcriptase inhibitors:

Non-nucleoside reverse transcriptase inhibitors are metabolised mainly through cytochrome P450 (CYP450) enzymes. Rifampicin induces CYP450, leading to a reduction in the plasma concentration of nevirapine by 30-40% and efavirenz by 20% - 25%. There is concern that reduced nevirapine concentrations will lead to emerging drug resistance and treatment failure. Increasing the dose of nevirapine to compensate for this interaction increases the risk of toxicity, and the risk of hepatotoxicity is already increased in patients with a low body mass index or with high CD4-lymphocyte counts.

It is therefore usually advised that nevirapine and rifampicin should not be used together, and that efavirenz be substituted for nevirapine. The problem is that efavirenz is teratogenic (and nationally over half of treated patients are women), there is currently no fixed dose combination with stavudine and lamivudine, and efavirenz based-treatment is more expensive. Moreover, there is evidence that, although plasma nevirapine levels are reduced by rifampicin, they still remain in the effective range, and outcomes in patients on rifampicin and nevirapine are still good. Malawi will therefore continue to use nevirapine-based regimens in association with rifampicin, and closely monitor the outcomes of patients.

Eligibility for treatment:

All patients with tuberculosis are potentially eligible for ART, because they are either categorised as WHO Clinical Stage 3 or 4. However, it is well known that TB can occur in HIV-positive patients with high CD4 counts (who therefore may not need ART). Specialist opinion may dictate that some HIV-positive TB patients have ART deferred if the CD4 count is felt to be too high.

When to start ART in a patient on anti-TB treatment:

In the initial phase of anti-TB treatment, ART will not be given because the patient is still sick, the pill burden will be high and there is a danger of immune reconstitution disease (see below). In severely immuno-compromised patients in specialist centres, consideration may be given to starting ART within 2 weeks of initial phase anti-TB treatment. Thus, in general, once the patient has completed the initial phase of treatment and started on the continuation phase of anti-TB treatment with rifampicin and isoniazide (RH), the patient will then be eligible for ART.
Provision of ART for TB patients on continuation phase RH

The following steps are recommended:

- During registration for anti-TB treatment, TB patients will receive HIV testing and counselling (provider-initiated HIV testing). HIV-positive TB patients will start on cotrimoxazole according to the current CPT policy.

- Once HIV-positive TB patients have completed their initial phase of anti-TB treatment, they will be started on RH.

- Patients will start straight away with the continuation phase of d4T/3TC/NVP. This is because rifampicin reduces plasma levels of NVP, and use of the starter pack will result in sub-therapeutic NVP levels. Patients will collect the monthly supply of d4T/3TC/NVP and also collect their monthly supplies of anti-TB treatment on the same day. CPT will be continued along with ART. Because of the added adverse effects of stavudine and isoniazid in causing peripheral neuropathy, patients should be given ½ tablet of pyridoxine daily (12.5mg daily).

**Table: ART with anti-tuberculosis treatment**

<table>
<thead>
<tr>
<th>Phase of Anti-TB Treatment</th>
<th>ART</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial Phase [RHZ(E)]</td>
<td>No ART</td>
</tr>
<tr>
<td></td>
<td>Prepare the patient with group counselling in initial phase</td>
</tr>
<tr>
<td>Continuation Phase (RH)</td>
<td>Start at continuation phase with four-weeks continuation pack of d4T/3TC/NVP</td>
</tr>
<tr>
<td></td>
<td>Every month the patient collects one month’s supply of RH and d4T/3TC/NVP</td>
</tr>
</tbody>
</table>

Management of patients already on ART who develop TB:

A proportion of patients who start ART for other reasons may develop TB. This most frequently occurs during the first three months of ART. The risk is higher if patients have a previous history of TB. Some of the patients who develop TB soon after starting ART may have had undiagnosed TB at the time of starting ART. Clinicians must have a low threshold for suspecting TB in both adults and children. If there is any suspicion of TB, the appropriate investigations (sputum smears, chest x-ray) must be undertaken. If TB develops when the patient is on ART, ART continues with d4T/3TC/NVP, and anti-TB treatment started in the usual way.
Other ART and anti-TB issues

- If patients on first line ART develop drug-resistant TB and need a second line anti-TB treatment regimen, then this can be given. Second line anti-TB treatment regimens do not contain rifampicin, and consequently there are no serious drug-drug interactions to be concerned about.

- If patients on second line ART (which contains protease inhibitors) develop TB, then the second line ART regimen will have to be modified as rifampicin and protease inhibitors cannot be given together with any degree of safety or efficacy. Specialist opinion must be sought about what this modified second line ART should be.

- If patients on second line ART develop drug-resistant TB and need a second line anti-TB treatment regimen, then this can be given. Second line anti-TB treatment regimens do not contain rifampicin, and consequently there are no serious drug-drug interactions to be concerned about.
TREATMENT OF HIV-POSITIVE PATIENTS WITH MALIGNANCY

HIV-infected patients have a dramatically increased risk of developing malignancies during the course of their illness, particularly Kaposi's Sarcoma, and lymphomas.

The presence of Kaposi sarcoma (KS) is usually ascertained clinically, whereas the diagnosis of lymphoma requires histological confirmation, only feasible at central level in Malawi.

One of the core elements of treatment for HIV-related malignancy is the provision of ART. In fact, in patients with benign, non-aggressive cutaneous forms of Kaposi’s sarcoma ARV therapy on its own is sufficient enough treatment. However, for most patients treatment of HIV-related malignancies should also include the use of cytotoxic drugs, if these are available. This strategy applies to patients with aggressive Kaposi’s Sarcoma (in which lesions are associated with a significant impact on functional and/or vital prognosis) or lymphoma. Even though not curative, the addition of cytotoxic therapy can significantly increase the patients’ quality of life and length of survival, although these drugs in their own right suppress immunity.

Cytotoxic drugs:

Bleomycin, Vincristine, Etoposide, Cyclophosphamide (to name only those available in Malawi) figure among the drugs ordinarily used in various protocols of mono- or preferably poly-chemotherapy. Steroids (prednisolone/dexamethasone ) may also be used in combination. Apart from vincristine, the other drugs are usually only available at central hospitals in Malawi. Radiotherapy, not currently available in Malawi, is occasionally indicated.

The drugs mentioned above, can be used with ART: there are no contraindications. However, some of the drugs are associated with a toxicity profile similar to ART, and this may require particular attention and monitoring. The common principal toxicities caused by the available cytotoxic and ARV drugs are shown below:-

- Vincristine and Etoposide may induce peripheral neuropathy, like Stavudine (d4T) and Didanosine (ddI)
- Bleomycin may cause muco-cutaneous reactions, like Nevirapine (NVP)
- Cyclophosphamide and Etoposide are myelotoxic, like Zidovudine (AZT). This association requires more frequent measurements of the full blood count .These drugs should only be used at sites with oncology expertise.

Management of Kaposi’s Sarcoma: ART in combination with vincristine monotherapy is the standard regime for aggressive and/or progressive disease in Malawi. In patients with mild to moderate disease which does not limit function ART can be given alone. For others, six weekly doses of vincristine may be started either before or concurrently with ART. (For more information refer to the Malawi HIV-management guidelines). KS immune reconstitution disease may occur at initiation of ART but has been found to be rare (1-2%) in a large cohort study in the West.
MANAGEMENT OF OCCUPATIONAL AND ACCIDENTAL EXPOSURE

Occupational exposure might place a health care worker (HCW) at a risk of HIV infection. Needle-stick injury is the most common occupational exposure, although exposure to other body fluids such as pleural, pericardial, ascitic, amniotic, synovial, cerebral spinal fluids, semen and vaginal secretions pose a risk for HIV infection.

The overall risk of HIV infection from occupational exposure is low. For example, from needle sticks the overall risk of becoming HIV-infected is 1 in 300. From mucous membrane exposure it is less than 1 in 1000.

HIV exposure for the purposes of interventions is classified as either:-

- low risk
- high risk.

**High risk:** Percutaneous injuries with hollow needles and large volumes of blood on to a mucosal surface from a source person who is known to be HIV-seropositive, or if there is a strong suspicion that the source is HIV-seropositive, are considered high risk exposures.

**Low risk:** All other exposures, including percutaneous injuries with solid needles, exposures to fluids other than blood, and exposures to the non-intact skin, are considered low risk exposures.

Exposure of blood or other fluids to the intact skin is not a risk in this context and does not require Post Exposure Prophylaxis (PEP).

Although there are several options for Post Exposure Prophylaxis (PEP), it is critical that health care workers minimise their risk of exposure to HIV infection. Therefore all body fluids should be considered potentially infectious and it is important to follow all universal infection control precautions.

**What to do after occupational exposure: low risk and high risk**

**Immediate measures:**
- Use soap and water to rinse any wound or skin site in contact with infected blood or fluid
- Rinse exposed mucous membranes thoroughly with water
- Irrigate generously any open wound with sterile saline or disinfectant solution (2-5 min)
- Eyes should be irrigated with clear water, saline or sterile eye irrigants.
- Report to the clinician on duty as soon as possible

**Post-exposure prophylaxis (PEP): low risk and high risk**

“PEP” refers to treatment of occupational exposures using ARV drugs. ART started immediately after exposure to HIV may prevent HIV infection, although this protection is not 100%. Treatment should be initiated within 1-2 hours of exposure, but if there are delays, PEP can still be started up to 72 hours after the exposure.
Operational considerations:

- Each health facility should have a bottle of **AZT/3TC** (60 tablets) kept in an agreed designated unit for easy, but secure, access.

- Following occupational exposure, a HCW should immediately report to the senior member of his/her unit and the designated PEP location where initial risk assessment will be done: a 3-day supply of AZT/3TC will be given. This should be started as soon as possible after the needle stick injury.

- The HIV status of the source patient should be determined whenever possible. If the source patient is HIV-positive, then PEP is indicated. If the source patient is HIV-negative, then this may be because the patient is in the window period of HIV-infection or in hospital because of primary HIV infection. Specialist advice may be sought about the need to continue or stop PEP, but in general the advice will be to continue the PEP because of the risk.

- The HCW must be strongly encouraged to undergo counselling and testing immediately or within 72 hours of exposure. If the HCW is HIV-positive, then PEP is not necessary and should be stopped. Moreover, taking dual therapy in an already HIV-infected patient may lead to the development of drug resistance. HIV-positive HCWs must be assessed for eligibility for ART.

- If the HCW is HIV-negative, then PEP is continued for a total duration of 30 days. HCWs must be counselled about side effects. Side effects are monitored clinically, and laboratory tests (eg, haemoglobin measurements for zidovudine) may be done according to indications.

- Follow-up HIV testing is done at 3 and 6 months. If the HIV test remains negative at 6 months, the HCW can be counselled that he/she has not been infected with HIV as a result of the exposure.

**Table: The PEP Regimen**

<table>
<thead>
<tr>
<th>DRUG</th>
<th>DOSE</th>
<th>FREQUENCY</th>
<th>DURATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zidovudine (AZT) 300mg/ Lamivudine (3TC) 150mg</td>
<td>One tablet</td>
<td>Twice a day (BD)</td>
<td>30 days</td>
</tr>
</tbody>
</table>

Dual therapy should be available at every health facility and at central medical stores. In cases of high risk exposure or when the source patient is already on ART, lopinavir/ritonavir two tablets twice a day can be added to the dual NRTI therapy: specialist advice is necessary in these cases.

**Documentation of PEP:**

Whenever PEP is given there should be formal documentation in a register that is kept centrally in the ART clinic. Every quarter, the number of persons in whom PEP is given should be recorded as part of the ART supervision.
MANAGEMENT OF HIV EXPOSURE THROUGH RAPE

Another group of persons to be offered Post Exposure Prophylaxis (PEP) is women, men and children who have been raped. Although the risk of acquiring infection from a single act of sexual intercourse is low, this kind of exposure (i.e., rape) is commonly associated with violence and genital tract trauma, which increases the risk of HIV transmission.

All persons who are HIV-seronegative and who have been raped, should be offered PEP. As with PEP after occupational injuries, the earlier it is administered the more effective it is. Clinicians must also ensure appropriate referral or treatment for other aspects of sexual assault (e.g., STI, emergency contraception, psycho-social support, criminal investigations).

The same procedures for PEP that have been described earlier in this section should be followed. If the victim is found to already be HIV-seropositive, then PEP should not be started or be stopped, and appropriate counselling and clinical referral made.

All persons involved with rape victims, including the police, must ensure that the rape victim is brought to hospital as an emergency before detailed questioning takes place in order not to delay PEP initiation. Health care workers must make their own decisions about the need for PEP, based on a history of penetrative sexual violence, and not be bound by the police report on whether rape has occurred or not.

The regimen is the same as PEP for occupational exposure. Zidovudine 300 mg plus Lamivudine 150 mg are given twice a day for 30 days: the appropriate dose schedules are followed for children as shown in Annex 3. Follow-up HIV testing is done at 3 months and 6 months.

For more information, please refer to Guidelines on Sexual Abuse and Rape from the Reproductive Health Unit, Ministry of Health, and the HIV Testing and Counselling Guidelines of the Ministry of Health.
MONITORING ART

REGISTRATION OF PATIENTS ON ART

Each patient who starts ART will be given a unique treatment unit ARV Registration Number. Each facility has a code for ARV (e.g., MCH for Mchinji District Hospital), and patients are given a unique number. This number is increased sequentially. For example, the first patient in a facility is given the number “01”. The thousandth patient is given the number “1000”. This number will be written on the patient master card and the patient identity card, and put into the ARV Register.

The system of patient registration is as follows:

ARV Patient Master Cards:

Each patient has a patient master card: for new patients and for follow-up patients. Cards for new patients (Annex 4) should have all registration data entered at the time when the patient starts ART. This includes:- ART registration number, name, address, age, sex, weight, height, whether the patient is a “transfer in” from another treatment unit, name of identifiable guardian, reason for starting ART, date of starting first line ART, dose of d4T/3TC/NVP, initial outcome status and concomitant use of cotrimoxazole preventive therapy. It is important to ask the patient if there has been previous exposure to ARV drugs.

The address is very important for follow-up purposes. The address wherever possible should be a physical address and should include a phone number. At the end of the address row, there is a yes/no box to be ticked where the patient agrees to be followed-up in the community in the event of a no-show at the clinic.

Patient master cards will be placed in a cellophane sleeve and these will be kept sequentially in hard back lever arch files. It is vital that these master cards are kept in an ordered sequence in arch back files. It is recommended that 50 master cards in their polythene sleeves be kept in one arch back file. All follow-up data are also recorded in the master card. At the end of the first year, a follow-up master card (also see Annex 4) is given to the patient and filed away in the same polythene sleeve as the first master card.

ART Patient Register:

Each facility has its own unique ART patient register. The Register has a left hand page and a right hand page (Annex 5). The left hand page consists of case registration data, and this includes:- ART number, year of registration, quarter, date of registration, name, age, sex, address, reason for ART, date of starting ART, name of guardian and treatment unit. The right hand page consists of patient outcomes (see below) and also at the end a column for the patient’s occupation and remarks. At the time of registration, the left hand page and right hand page is completed, with patients being registered as “Alive” and on “Start”. (See below).
Patient Identity Cards:

Patient identity cards (Annex 6) will be smaller and will contain the same basic information as the patient master card. This will include:- ART registration number, name, address, age, sex, weight, whether the patient is a “transfer in” from another treatment unit, name of identifiable guardian, the reason for starting ART, the date of starting first line ART, the dose of d4T/3TC/NVP, the date of starting second line ART and the reason. Patients will be given their own ART identity cards, which serve as a reference for all follow-up visits and if and when the patient becomes ill and is admitted to another facility for treatment.

Patient stamps in Health Passports:

An alternative identity reference is a stamp placed in the health passport. Special stamps are provided in each facility, which exactly mirror the patient identity card. The relevant information is written into the stamp in the passport.

“Transfer-in”:

Patients who transfer in from another site are registered as follows. A transfer in patient should always bring the ART patient master card from the previous facility. At the new facility, the new ART number assigned to the patient replaces the previous number on the master card and the patient is indicated on the master card as a “transfer-in”.

In the ART register, the transfer-in patient is written into the next available row with the new number and the demographic and clinical details. The date of registration is recorded in the appropriate column. The date first started on ARV drugs is the date the patient was first started on ART in the previous facility. Under reason for ART, the staging condition by which the patient started ART at the previous facility is recorded and the patient is also indicated in this column as a “transfer-in”.


MONITORING AND RECORDING TREATMENT RESPONSE

Patient visits:

Patients will be seen two weeks after starting ART, and then 4-weekly. After 6 months, if stable and adherent and if they have attended another formal group counselling session, review visits can be increased to once every two months and sometimes to once every three months.

At these follow-up visits, patients will:

- Have their weight recorded and in children the height as well
- Be asked about their general health
- Be asked about whether they are ambulant or in bed
- Be asked about whether they are working
- Be asked about side effects and symptoms (see Table below)
- Have their returned pill bottles inspected to count the remaining drugs
- Collect another one-month, two-month or three-month supply of drugs
- Be asked about the importance of strict adherence to therapy
- Be asked about CPT

Table: Check List of Symptoms for patient attending the Clinic

<table>
<thead>
<tr>
<th>Symptom</th>
<th>YES</th>
<th>NO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Vomiting</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Weight loss</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Rash</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Pain or numbness in your legs</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Cough</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Yellow eyes</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Any unwanted changes in body shape</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Any other new symptoms</td>
<td>YES</td>
<td>NO</td>
</tr>
</tbody>
</table>

*If any of the symptoms are recorded as YES, then the patient must be seen by a clinician and be assessed.
*If all symptoms are recorded as NO then the patient can be dispensed a bottle of ARV drugs

The information about weight and the answers to questions will be recorded in the patient master cards (Annex 4). In order to avoid “ghost patients”, patients themselves or their identifiable guardians will collect their own supply of drugs. Guardians are permitted to collect drugs on behalf of a patient for a maximum of two months: after this the patient must be seen at the clinic and must collect his/her own supply of drugs. Thus, on two monthly follow-up visits it is expected that a guardian can only collect drugs once and the next visit the patient must attend. At three-monthly visits, the patient must attend.
Definition of Standardised monthly outcomes:

Standardised outcomes will be monitored at every follow-up visit. The Tables below show and explain the standardised outcomes.

**Table: Outcome status:**

<table>
<thead>
<tr>
<th>Outcome status</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alive and on ART (A) [note 1]</td>
<td>Patient who is alive, on ART at the facility where he/she is registered, and has collected his/her own supply of drugs</td>
</tr>
<tr>
<td>Dead (D)</td>
<td>Patient who has died for any reason while being registered on ART</td>
</tr>
<tr>
<td>Defaulted (DF) [note 2]</td>
<td>Patient who is not seen at all during a period of 3 months</td>
</tr>
<tr>
<td>Stopped (Stop) [note 3]</td>
<td>Patient who has stopped treatment completely either because of side effects or other reasons</td>
</tr>
<tr>
<td>Transfer-out (TO) [note 4]</td>
<td>Patient who has transferred out permanently to another treatment unit</td>
</tr>
</tbody>
</table>

**Note 1:**
A patient who is alive is further categorised according to the type of ART regimen he/she is taking.

*Start (Start):* i.e., the patient is on the first line regimen

*Substituted (Sbs):* i.e., the patient experienced side effects from the first line regimen and has changed to an alternative first line ARV regimen

*Switch (Switch):* i.e., the patient has switched to the second line regimen because of ART failure (see definition of ART Failure on page XXX). Specialist opinion must always be sought before classifying a patient as “Failure”.

**Note 2:**
A patient is declared a defaulter if he/she has not appeared at the clinic 2 months after the next appointed date. The date of default is the date at which the default classification is made. The box shows how to define defaults depending on whether follow-up is 1-, 2- or 3-monthly.

<table>
<thead>
<tr>
<th>Follow-up</th>
<th>Definition of default</th>
</tr>
</thead>
<tbody>
<tr>
<td>One-monthly</td>
<td>3 months after last recorded visit made by patient</td>
</tr>
<tr>
<td>Two-monthly</td>
<td>4 months after last recorded visit made by patient</td>
</tr>
<tr>
<td>Three-monthly</td>
<td>5 months after last recorded visit made by patient</td>
</tr>
</tbody>
</table>
Note 3:
A patient may stop or be withdrawn from treatment because of a) unacceptable side effects despite substituting an alternative first line regimen, b) poor adherence with medication, c) other reasons such as not wishing to continue any longer on ART. Patients are to be recorded as “STOP” and the reasons for stopping or withdrawal are to be indicated in the patient master card.

Note 4:
If a patient transfers permanently out of a district to another ART facility, this is recorded in the patient master card and also in the ART Register. The patient takes that master card to the new district, where it is indicated that he/she is a transfer-in. The patient is given a new ARV registration number, and is placed in the cohort of the new district at the time that the patient registers in the new district. The ART Programme realises that this patient is counted twice in terms of case finding.

Table: Ambulatory status:-

<table>
<thead>
<tr>
<th>Ambulatory (Amb)</th>
<th>Able to walk to the treatment unit and walks around at home unaided or in the case of a child able to perform age-specific daytime activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bed (Bed)</td>
<td>Unable to walk to the treatment unit and spends most of the time in bed at home</td>
</tr>
</tbody>
</table>

Table: Work (or school) status:-

<table>
<thead>
<tr>
<th>Yes (Yes)</th>
<th>Engaged in productive work, or in the case of children being at school. Productive work also applies to work which is not paid, i.e., being a housewife</th>
</tr>
</thead>
<tbody>
<tr>
<td>No (No)</td>
<td>Not engaged in previous work or employment</td>
</tr>
</tbody>
</table>

Table: Side effects:-

<table>
<thead>
<tr>
<th>Yes (Yes) : specify side effects</th>
<th>Side effects stated by patient after questioning from health worker:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eg (Yes-PN)</td>
<td>PN = peripheral neuropathy</td>
</tr>
<tr>
<td>(Yes-HP)</td>
<td>HP = jaundice, liver failure</td>
</tr>
<tr>
<td>(Yes-SK)</td>
<td>SK = cutaneous hypersensitivity</td>
</tr>
<tr>
<td>(Yes-LA)</td>
<td>LA= lactic acidosis</td>
</tr>
<tr>
<td>(Yes-LD)</td>
<td>LD= lipodystrophy</td>
</tr>
<tr>
<td>(Yes-AN)</td>
<td>AN = anaemia</td>
</tr>
<tr>
<td>No</td>
<td>No side effects stated by patient</td>
</tr>
</tbody>
</table>
Pills left in ARV container:

ARV tablets remaining from the last visit should be counted at every visit and recorded on the master card. This serves a) to remind the patient that it is crucial that tablets are taken regularly and b) to measure adherence in order to counsel the patient if there is a problem. For this purpose, the clinic should insist that all remaining tablets are always brought back to the clinic for a physical count. It is useful to ask for any additional tablets left at home. Tablets left at home should be included for the calculation of adherence and the next appointment if this information is believed to be reliable, but should be ignored otherwise.

There are two ways of measuring adherence, which should be 95% or more to prevent the development of drug resistance:

The simple way (used in sites with no electronic register) is to count the number of pills in the container in adults on first line regimen only. It is too difficult to do this for other regimens or with children. The table below shows the number of tablets left in a container that indicate whether adherence is 95% or greater.

<table>
<thead>
<tr>
<th>Appointment interval</th>
<th>Tablets dispensed at previous visit</th>
<th>100% adherence (tablets remaining at current visit)</th>
<th>95% adherence (tablets remaining at current visit)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 weeks</td>
<td>60</td>
<td>4</td>
<td>8</td>
</tr>
<tr>
<td>8 weeks</td>
<td>120</td>
<td>8</td>
<td>16</td>
</tr>
<tr>
<td>12 weeks</td>
<td>180</td>
<td>12</td>
<td>24</td>
</tr>
</tbody>
</table>

If the container is not returned to clinic or the patient comes late to clinic, self-reporting of drug adherence will be carried out: in these circumstances the registration officer will decide whether or not there is 95% adherence. At every visit, health personnel must talk to the patient about the importance of drug adherence.

The more complicated way (used in sites with an electronic register or with a calendar and calculator) is to calculate adherence as a percentage: \( \text{actual consumption of tablets since last visit} / \text{Expected consumption of tablets since last visit} \). The general adherence calculation uses the following information:

\[
\text{Adherence \%} = \frac{(B-D)}{(A \times C)}
\]

Low calculated drug adherence can be due to the following reasons:

a) Visit on or before the appointment date but too many tablets remaining

b) Late visit, even if no tablets are remaining. In this case, calculate the number of tablets missed and indicate as negative pill count on patient master card (e.g. ‘-14’ if 7 days late after running out of tablets)
Calculated adherence will be greater than 100% if there are fewer than expected tablets remaining. This can be due to poor adherence (overdosing, patient has taken more tablets than prescribed) or an indication for tablet loss or sharing.

**Managing the remaining pills in the container:**

Patients should not be allowed to accumulate large numbers of tablets in the course of their visits because they will eventually be at risk of taking expired drugs. Even if patients are 100% adherent, accumulation will occur unless appointments are delayed to allow patients to ‘use up’ remaining pills before the next dispensing. Patients should usually be given a new bottle and instructed to take all remaining before opening the new bottle.

The strategy for delaying appointments has to take account of the days that the clinic is open for follow-up visits. As a general rule, delayed appointments should only be given once the patient has accumulated more than 8 tablets and at least as many tablets as are needed to ‘reach’ a later clinic day. In any case, the patient should be left with 2 days worth of tablets on the new appointment date as a ‘safety-buffer’. When calculating delayed appointments, great care has to be taken not to schedule appointments for weekends or public holidays.

**Recording standardised treatment outcomes:**

Standardised outcomes and weight, with the date of the visit, are recorded in the appropriate row in the patient master card every time the patient reports to the clinic.

If the patient’s outcome changes from “Alive and from “Start”, this is recorded in the master card and also recorded in the ARV Register with the date or month of the change. If a patient is not seen for 3 months, 4 months or 5 months depending on the time period of follow-up, he/she is recorded in the master card and the register as “default” with the date being 3 months, 4 months or 5 months since the last recorded visit.

Outcomes are dynamic. If a patient is recorded as “default” and subsequently the outcome is discovered to be “death” or “transferred out”, then the outcome is changed to “death” or “transfer out” with the date or month of this outcome.

If the patient transfers out to another district and sometime in the future transfers back to the first district where he/she was registered, the patient maintains the original ARV number and the outcome is changed back from “transfer out” to “alive and on ART”.
ADHERENCE TO ART

Patient adherence is a key factor in the success of ART. Every attempt should be made to ensure that the patient is 95% adherent to therapy. Adherence is measured monthly either by a) pill counts or b) by self-reporting.

At the ART staging assessment, every patient is strongly encouraged to identify a guardian to remind, facilitate and support the patient in taking medications on a regular and timely basis. The patient and the guardian should attend, wherever possible, the first group counselling session at which the ART staff with the help of the Standard Flip Chart provides education about ART and the importance of adherence. This form of treatment is termed “ERT”, empowered reinforced therapy, or “GST”, guardian supported therapy, which both may include directly observed treatment. At each clinic visit, the returned bottle must be counted for “pills”, and a record made of the number of pills left in the container. If pills are not counted because the patient is late or has left the pill container behind, self–reporting of adherence is carried out. At the same time, the patient must be counselled about the importance of strict adherence to treatment. Treatment units should have an ample supply of IEC (Information, Education and Communication) patient leaflets and calendar booklets, explaining the importance of good drug adherence and the dangers of poor adherence.

If, despite consultation with the patient and guardians, adherence to treatment is a problem or the patient is not compliant with monthly visits, the clinician may decide, after appropriate consultation, to withdraw the patient from therapy.

Operational research should be conducted on a regular basis to determine drug adherence at community level.

Drug Adherence in Children

To promote drug adherence the following steps are recommended:

A. At HIV-ARV clinics ARV-drugs must always be available

B. Before initiating ART in children
   a. Two persons responsible for drug administration should be clearly identified, so that if one is ill or away there is always a caregiver available
   b. Caregivers should be provided with a written medication-schedule emphasising the need for a modified dosing scheme during the first two weeks of therapy, together with the need to report promptly the appearance of rash or other new symptoms
   c. Caregivers should repeat the dosing schedule to make sure that the schedule is understood
d. Health care worker hands out and explains to caregivers and children the paediatric ART calendar booklet

e. Caregivers attend an education session focusing on
   i. Understanding the medication rationale and schedule
   ii. Practising pill swallowing
   iii. Integrating medication intake into the regular routines of the child and family
   iv. Providing information about opportunities to further improve adherence (e.g. patient support groups, positive reinforcement of good medication intake, reminder systems, etc.)

f. Facilitators of the education sessions should use the National Paediatric ART Flip Chart

C. At each subsequent visit
   a. The d4T/3TC/NVP regimen should be repeated by the caregiver
   b. Caregivers should be asked about the potential adverse effects of therapy
   c. “2 books and bottle”: together with the health passport and the calendar booklet the ART bottles, either empty or with remaining tablets, need to be brought to the clinic
   d. Treatment adherence needs to be explored by a health care worker using pill counts. In addition, the health care worker should check ticks in the ART Calendar booklet
   e. Caregivers are instructed to follow given appointments (table provided in the last page of the calendar booklet) or return to the clinic one week before it is anticipated that ARV drugs will run out

D. Advice about pill taking
   a. If the child vomits the tablets or solutions within half an hour of ingestion, then the dose must be repeated
   b. Tablets are not to be pre-cut
   c. Caregivers should be given regular supplies of pill cutters and the ART staff must explain how to use them to cut pills at home
MONITORING AND MANAGING DRUG TOXICITY

Adverse effects of ART using the First Line Regimen

Clinical monitoring of side effects will be carried out during treatment. Routine laboratory monitoring is not required. Health personnel can monitor adverse effects in the following two ways. First, they must teach patients how to recognise symptoms of common adverse effects and to report if they develop such symptoms. Second, they must specifically ask about symptoms when patients report to collect drugs.

Side effects can be minor or major:

*Minor side effects* include headaches, nausea, abdominal pain, diarrhoea and difficult in sleeping at night. These should be managed symptomatically.

*Major side effects are divided into immediate and long term.*

*Immediate side effects* include peripheral neuropathy, hepatitis, pancreatitis and cutaneous hypersensitivity. *Long-term side effects* include lactic acidosis, lipodystrophy syndrome and also peripheral neuropathy.

Management of major side effects is discussed below.

*Table: Major side effects with d4T/3TC/NVP*

<table>
<thead>
<tr>
<th>Immediate Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peripheral Neuropathy</td>
</tr>
<tr>
<td>Hepatitis</td>
</tr>
<tr>
<td>Pancreatitis</td>
</tr>
<tr>
<td>Cutaneous hypersensitivity</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Long Term Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peripheral Neuropathy</td>
</tr>
<tr>
<td>Lactic acidosis</td>
</tr>
<tr>
<td>Lipodystrophy syndrome</td>
</tr>
</tbody>
</table>

Management of peripheral neuropathy

This is due to the stavudine (d4T) component. Patients may have pre-existing peripheral neuropathy before starting ART, but this should not stop the initiation of ART as it may get better on treatment.

Peripheral neuropathy should be diagnosed if the patient complains of pain, paraesthesiae, numbness or weakness of the lower limbs. The usual presentation is gradual worsening over several months and is predominately sensory in nature.
Risk factors for peripheral neuropathy should be minimised. For example, TB patients on isoniazid should be given pyridoxine 10 mg (or 12.5mg, depending on the formulation available) daily before starting ART. Patients should be advised not to take alcohol.

The following are recommended steps in the management of peripheral neuropathy, although clinical judgement must be used about how to progress through these steps:-

- First, treat the patient with multi-vitamins and amitryptiline 25 mg in the evening, increasing to 50mg in the evening if no response after 4 weeks
- If this combination is unsuccessful, then an anti-inflammatory drug such as indomethacin 50 – 75 mg nocte or ibuprofen 400 mg three times a day should be added to the symptomatic treatment regimen
- If symptomatic treatment is unsuccessful and the peripheral neuropathy continues to be severe and progressing, the ARV regimen may have to be stopped and replaced with an alternative first line regimen: Zidovudine (AZT) + Lamivudine (3TC) + Nevirapine (NVP). The dose for adults is one tablet of AZT+3TC twice a day plus one tablet of NVP twice a day (ie, four tablets a day). The dose for children is shown in Annex 3.
- If the Haemoglobin is less than 8g/dl at the time of substitution, consult with a specialist before commencing therapy because AZT is not recommended. In this situation, the usual alternative regimen will be Tenofovir (TDF) + Lamivudine (3TC) + Nevirapine (NVP).

[severe, rapidly progressive neuropathy of late onset with weakness or upper limb involvement should prompt a suspicion of lactic acidosis – see below]

Management of pancreatitis

This is usually due to the stavudine or, more rarely, the lamivudine component.

Pancreatitis should be suspected if the patient develops severe upper abdominal pain, nausea and vomiting. Confirmation of the diagnosis is by finding a raised serum or urine amylase (or lipase), abnormal abdominal ultrasound and abnormal abdominal CT scan. In the absence of these investigations the diagnosis must be made clinically.

A diagnosis of pancreatitis requires that the d4T/3TC/NVP regimen be stopped and this must not be re-introduced. Once the pancreatitis has resolved, treatment is changed to: Zidovudine (AZT) + Lamivudine (3TC) + Nevirapine (NVP). The dose for adults is one tablet of AZT+3TC twice a day plus one tablet of NVP twice a day (ie, four tablets a day). The dose for children is shown in Annex 3. If the Haemoglobin is < 8g/dl at the time of substitution, consult with a specialist before starting therapy because AZT is not recommended. In this situation, the usual alternative regimen will be Tenofovir (TDF) + Lamivudine (3TC) + Nevirapine (NVP).
Management of hepatitis

This is due to the nevirapine component.

Hepatitis should be diagnosed if the patient is jaundiced, or suspected if the patient develops anorexia and vomiting particularly if the patient becomes confused as well. In the case of jaundice or high suspicion of hepatitis with impending liver failure, d4T/3TC/NVP should be stopped. If possible liver function tests should be performed to determine the degree of abnormality of the liver enzymes. If the transaminases are higher than 5 times the upper limit of normal, this is an indication to stop ART.

ART must be stopped and d4T/3TC/NVP should not be restarted. Another ART regimen needs to be given once the hepatitis has resolved. This substitution is complicated by the fact that nevirapine has a long half life and the triple therapy drug should not be stopped completely at once, otherwise NVP drug resistance may be allowed to occur. The following steps are therefore recommended:

- Stop d4T/3TC/NVP and immediately
- Start d4T and 3TC, one tablet twice a day, and continue for one week, then
- Stop d4T and 3TC, and wait until hepatitis has settled – in general wait for 4 weeks after the jaundice has settled, then
- Start stavudine (d4T) + lamivudine (3TC) + efavirenz (EFV). The dose for adults is d4T+3TC one tablet twice a day (from the 60-tablet bottles) and EFV one tablet daily. The dose for children is shown in Annex 3.

Management of cutaneous hypersensitivity

This is due to the nevirapine component.

In the first two weeks: If a rash occurs in the first two weeks, then the patient must be closely observed either in or out of hospital. There should be no escalation of the dose of nevirapine, which remains at 200 mg once a day. If the rash improves or remains stable, then the dose of nevirapine can be increased to 200 mg twice a day.

After the first two weeks: Any new skin manifestation requires that the patient be assessed at hospital ART clinic. If itching occurs then d4T/3TC/NVP should be continued and an antihistamine added, such as chlorpheniramine 4mg three times a day. If a rash develops in addition to itching, the patient should be carefully assessed. Other causes for a rash should be ruled out, eg scabies, CTX. If the rash becomes worse, and if there is mucosal membrane involvement, the ART must be stopped.

If the skin reaction is severe and accompanied by any of the following, ART must be stopped and the patient must be admitted to hospital:

a) exfoliative dermatitis or toxic epidermal necrolysis
b) mucous membrane involvement
c) hypotension
The patient should be cared for in a side ward. The patient may need intravenous fluids and antibiotics to cover secondary infections, which almost invariably arise in these circumstances. Good nursing care is essential: blisters must not be opened; clean bedding must be provided daily, if possible, from theatre. Many physicians give steroid treatment, although there is no firm evidence that this helps and it may do harm.

Once the rash has resolved, d4T/3TC/NVP should not be restarted. Another ART regimen needs to be given. This substitution is complicated by the fact that nevirapine has a long half life and the triple therapy drug should not be stopped completely at once, otherwise NVP drug resistance may be allowed to occur. The following steps are therefore recommended:

- Stop d4T/3TC/NVP and immediately
- Start d4T and 3TC, one tablet twice a day, and continue for one week, then
- Stop d4T and 3TC, and wait until the rash has settled, then
- Start stavudine (d4T) + lamivudine (3TC) + efavirenz (EFV).

The dose for adults is d4T+3TC one tablet twice a day (from the 60-tablet bottles) and EFV one tablet daily. The dose for children is shown in Annex 3.

Long term side effects:

d4T/3TC/NVP may be associated with long term side effects, such as lactic acidosis and lipodystrophy syndrome. These effects do not usually occur until the patient has been on ART for at least 6 months.

*Lactic acidosis:*

This is a rare, but potentially fatal side effect with a 50% mortality rate, which is correlated to the lactic acid level in the blood. It is difficult to diagnose under resource-poor conditions and collection methods are challenging. For example, blood sampling needs to be without tourniquet and blood needs to be delivered to the lab on ice for processing within 4 hours. Overdiagnosis due to faulty collection methods may occur. The pathogenesis is believed to be due to mitochondrial toxicity of NRTIs. Stavudine has the highest risk, zidovudine a lower risk and tenofovir the lowest risk.

Patients typically present with fatigue, weakness, nausea, vomiting, abdominal pain or distension, muscle pains, weight loss, palpitations and shortness of breath. There may also be an acute or sub-acute onset sensory or motor neuropathy with rapid ascending weakness. In particular, the triad of abdominal complaints, weight loss and severe neuropathy in a previously stable patient should make the clinician suspect lactic acidosis. The diagnosis should be considered if the above symptoms develop fairly rapidly over a few days to weeks in a previously stable patient, particularly if they are at high risk (e.g., with obesity).

Confirmation of the diagnosis is by a low serum bicarbonate, elevated blood lactate and high creatine phosphokinase, all of which are difficult to measure in Malawi. If the diagnosis is suspected clinically, specialist or HIV Unit advice should be sought.
The most important therapeutic intervention is to STOP the ART. Symptoms and signs can take several weeks to resolve.

Once the symptoms have resolved, the patient can be started on AZT+3TC+NVP, and must be carefully observed. The substituted regimen should usually be started no sooner than 2 months after stopping the first line ART regimen. If there are any recurrences of the same symptoms or signs, the ART must be stopped and specialist opinion sought. In this situation, the usual alternative regimen will be Tenofovir (TDF) + Lamivudine (3TC) + Nevirapine (NVP).

The risk of lactic acidosis in increased in a) pregnancy, b) obesity with a high body mass index, c) concomitant use of metformin, d) heavy alcohol consumption, and e) alcohol binge drinking.

A mild elevation of lactic acid levels without symptoms can occur (asymptomatic lactic acidemia) which may be due to a faulty collection method. Treatment in asymptomatic patients should not be changed.

**Lipodystrophy syndrome or fat redistribution syndrome:**

This is usually seen in patients taking protease inhibitors, although it can occur with any antiretroviral drug and particularly stavudine (d4T). Clinical features include central obesity and peripheral fat wasting of the face, limbs and buttocks. There is often associated hyperglycaemia and hyperlipidaemia. If the diagnosis is suspected, this should be discussed with a specialist. One possible treatment option is to substitute AZT for d4T, and change the patient to AZT+3TC+NVP or again consider Tenofovir (TDF) + Lamivudine (3TC) + Nevirapine (NVP).

**Alternative and Second Line Regimens: adverse effects and their management**

<table>
<thead>
<tr>
<th>Antiretroviral drug</th>
<th>Side effect</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zidovudine</td>
<td>Anaemia</td>
<td>Stop and consider other management if HB drops below 8g/dl Stop and replace the drug Management as with NRTIs</td>
</tr>
<tr>
<td></td>
<td>Myopathy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lactic acidosis</td>
<td></td>
</tr>
<tr>
<td>Efavirenz</td>
<td>CNS effects eg, confusion</td>
<td>Take the drug last thing at night Management as with NVP Management as with NVP Avoid pregnancy</td>
</tr>
<tr>
<td></td>
<td>Rash</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hepatitis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Teratogenicity</td>
<td></td>
</tr>
<tr>
<td>Tenofovir</td>
<td>Renal injury</td>
<td>Stop TDF Stop TDF</td>
</tr>
<tr>
<td></td>
<td>Osteoporosis (children esp)</td>
<td></td>
</tr>
<tr>
<td>Lopinavir/ritonavir</td>
<td>Gastro-intestinal</td>
<td>Symptomatic Avoid drug-drug combinations</td>
</tr>
<tr>
<td></td>
<td>Interaction with other drugs – rifampicin, oestrogen</td>
<td></td>
</tr>
</tbody>
</table>
Abacavir | Hypersensitivity reaction (multi-organ syndrome with fever, rash, gastrointestinal effects, malaise and respiratory symptoms) | Stop Abacavir and other ART drugs | Do NOT rechallenge after suspected hypersensitivity

Didanosine | Neuropathy Pancreatitis | Management as with stavudine | Management as with stavudine

If patients develop severe toxicity to efavirenz, they may need to change to a protease inhibitor. If AZT or TDF have to be stopped, specialist opinion must be sought about alternative medications or alternative ways of managing the patient.

**DRUG – DRUG INTERACTIONS**

ARV drugs may interact with other medications. The table below shows the significant interactions.

<table>
<thead>
<tr>
<th>ARV Drug</th>
<th>Contra-indicated Use with great care/specialist advice</th>
<th>Dose adjustment required (of either ARV, combined drug or both)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stavudine- Lamivudine- Nevirapine</td>
<td>ketoconazole, zidovudine, St. John's wort</td>
<td>oral anti-contraceptives (additional method required), ganciclovir, amodiaquine, lumefantrine*</td>
</tr>
<tr>
<td>Zidovudine</td>
<td>stavudine</td>
<td>ganciclovir</td>
</tr>
<tr>
<td>Efavirenz</td>
<td>astemizole, terfenadine, midazolam, triazolam, cisapride, ergot alkoids, St. John's wort, voriconazole, amodiaquine</td>
<td>simvastatin (and other statins), rifabutin, warfarin, clarithromycin, lumefantrine*</td>
</tr>
<tr>
<td>Tenofovir DF</td>
<td>didanosine</td>
<td>didanosine</td>
</tr>
<tr>
<td>“Aluvia” (Lopinavir/Ritonavir)</td>
<td>rifampicin, astemizole, terfenadine, flecanide, propafenone, simvastatine, lovastatine, midazolam, triazolam, pimozone, cisapride, ergot alkoids, St. John's wort, rifapentine, phenytoin</td>
<td>rifabutin, clarithromycin, methadone, atorvastatin, pravastatin, ketoconazole, drugs for erectile dysfunction, carbamazepine, phenobarbitone, warfarine, atovaquone, amodiaquine, halofantrine, lumefantrine*</td>
</tr>
<tr>
<td>Drug</td>
<td>Additional Treatment Required</td>
<td>Antiretroviral Drugs Required</td>
</tr>
<tr>
<td>----------</td>
<td>-------------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>Abacavir</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Didanosine</td>
<td>stavudine, ribavirin</td>
<td>tenofovir DF, ketoconazole, fluoroquinolones</td>
</tr>
</tbody>
</table>

*part of the new first line anti-malaria treatment, lumefantrine+artemether (LA)

**MONITORING AND MANAGING IMMUNE RECONSTITUTION**

In patients who are severely immunocompromised (for example, with a CD4 lymphocyte count < 50/mm³), the initiation of ART may be associated in the first one to three months with an increase in the inflammatory response as a result of immune reconstitution.

There are two types of Immune Reconstitution Disease (IRD).

1. Infections which were latent before the start of ART and develop into clinical illness on ART; for example, TB or cryptococcal meningitis

2. Infections and diseases that were already diagnosed and even treated before the start of ART and which become clinically worse on ART: for example, TB and KS

The clinical illness resulting from immune reconstitution is termed a paradoxical response. The clinical spectrum of paradoxical responses includes fever, lymphadenopathy, lung and central nervous system involvement, depending on the infection or disease in question.

Paradoxical reactions should be managed according to the presenting illness, and may require aspirin and non-steroidal anti-inflammatory drugs (such as ibuprofen), antibiotics and sometimes cortico-steroids. In general, first line ART should be continued.

One special example of immune reconstitution is a patient developing overt tuberculosis soon after starting ART. In this situation, the first line ART with d4T/3TC/NVP can be continued and anti-TB treatment commenced.
COHORT ANALYSIS OF TREATMENT OUTCOME

Monitoring may be done manually and electronically.

Monitoring will be done every quarter. In the month following the end of one quarter, the supervision and monitoring forms will be completed. For example, for the quarter 1st January to 31st March, the supervision and monitoring forms will be completed in April.

For ARV treatment, there are three data sets to be completed:-

1) **Quarterly ARV Cohort Analysis.** The updated quarterly information for the most recent quarterly cohort of patients started on ART will be entered into the data set (Annex 7). The health care worker in charge of the ART clinic treatment unit will be responsible for completion of this data set. Details will be checked during supervisory visits.

2) **Cumulative ARV Quarterly Analysis.** This data set is completed every quarter, and represents a cumulative analysis of case finding data and treatment outcome data on all patients ever started on ART (Annex 7). The health care worker in charge of the ART clinic treatment unit will be responsible for completion of this data set. Details will be checked during supervisory visits.

3) **Group Cohort Treatment outcomes.** 12-monthly, 24-monthly and 36-monthly treatment outcomes will be determined based on quarterly cohorts being placed on therapy, the quarterly cohorts selected according to the censor date of the quarterly and cumulative analysis. For example, if the censor date is December 31st 2007, the 12-month treatment outcomes are determined in the patients started between October 1st and December 31st 2006; the 24-month treatment outcomes are determined in the patients started between October 1st and December 31st 2005; and the 36-month treatment outcomes are determined in the patients started between October 1st and December 31st 2004.

The HIV Unit and the ART team at the facility will keep copies of the completed quarterly and cumulative cohort analyses. The ART team will keep the originals in a special hard arch-back file.
Notes on completing the cohort analysis:

An example of a completed cumulative cohort analysis is provided in Annex 8.

Case finding data:

For the number of patients registered in the quarter and in the cumulative cohort,
Males and females must add up to the total number
Adults and children must add up to the total number
Occupation details must add up to the total number
Number with Stage 3 + Stage 4 + CD4 count must add up to the total number

In addition, the number of patients with PTB, EPTB, KS and referred from PMTCT
are entered into the data sets.

The MOH also obtains data on the number of patients who received Post Exposure
Prophylaxis (PEP) in the quarter.

Treatment outcome data:

Outcomes are censored on the last day of the quarter in question. Thus, in the
quarterly analysis from October to December and cumulative analysis up to
December, the last day of census is 31st December. Also outcomes such as
ambulatory, at work, side effects and pill counts are done for the last month of the
quarter.

Notes on the calculations:

For the number of patients registered in the quarter and in the cumulative cohort,
the number alive on ART+ deaths + defaults + stops + transfer-outs must add up to
the total number registered

For patients alive and on ART,
the number on Start + Substitute + Switch must add up to the number alive

For patients alive and on ART,
the number ambulatory, at work, and with side effects are recorded
the number with a pill count done and the number with pill count 8 or less is recorded

For patients who have died, the number dying in month 1, month 2, month 3 and
month 4 and beyond is documented. These numbers must add up to the total number
of patients who have died.

The quarterly cohort analysis provides data on the number of new patients started on
ART in the previous quarter, and enables the facility and HIV Unit to check whether
the units (low burden, medium burden, high burden) are meeting their targets. This
helps with drug procurement. It also allows the unit and facility to see trends in the
type of patients being enrolled to ART
The cumulative Analysis Form provides data on all patients ever started on ART, and enables the facility and HIV Unit to have regular up to date information on:-

- number of patients ever started on ARV drugs
- number of patients alive and currently taking ARV drugs
- number of patients currently on ART with drug adherence rates > 95%
- number of patients who have died since starting ARV drugs
- number of patients who have defaulted since starting ARV drugs
- number of patients who have been substituted to an alternative first line regimen
- number of patients who have failed ARV drugs and been switched to a second line regimen, indicating problems with the first line ARV regimen
- number of patients on ART who are ambulant or in the case of children who are engaging in age-specific daily activities
- number of patients on ART who are engaged in productive work

This information is used for quarterly and annual reports and for quantifying drug orders.

**SURVEILLANCE FOR ARV DRUG RESISTANCE**

Resistance testing is carried out, either by genotype testing or phenotype testing. Genotype testing looks for mutations on the reverse transcriptase or protease genes that impart partial or complete resistance to NRTIs, NNRTIs or PIs. Phenotype testing looks at the concentration of ARV drugs necessary to inhibit a certain percentage of the HIV isolates. Both techniques require sophisticated technology and skilled staff, and are very expensive.

In Malawi, it will not be possible to monitor for drug resistance on an individual level. However, two surveillance systems have been set up at sentinel sites around the country. First, there is monitoring of patients who have been on ART for 12 months. They have blood taken for viral load and genotype testing at 12 months after starting the first line ART regimen. The data provide information on a) the proportion of patients with complete viral suppression 12 months after the start of therapy and b) the pattern of genotype resistance patterns in those with detectable virus.

Second, in young women presenting at antenatal clinics with a first pregnancy, blood is taken for viral load and viral genotype patterns. The data provide information on the resistance patterns of HIV circulating currently in persons in the Malawian population who have not been exposed to ART.

For both surveillance systems, the epidemiology unit of CHSU is the co-ordinating body. Blood samples will be sent to CHSU for onward transmission to USA for the genotype testing. Results will be fed back to the MOH and disseminated nationally.
SUPERVISION AND NATIONAL DATA COLLECTION

Supervision is currently co-ordinated by the HIV Unit, working with partners to provide supervision, mentorship, monitoring and evaluation every three months to all ART delivery sites in the country. A structured form is used (Annex 9), in which qualitative data are collected on a) the use of ART Registers and ART patient master cards, ART clinic functions, b) ARV and specific OI drug stocks, c) quarterly and cumulative analysis, d) specific HIV-related diseases such as TB, KS, cryptococcal meningitis and oesophageal candidiasis, e) use of CD4 machines, f) number of persons receiving PEP in a quarter, and g) 12-month, 24-month and 36-month group cohort treatment outcome analysis.

ANTIRETROVIRAL DRUG SUPPLY AND USE

All ARV drugs for use in Malawi have a WHO pre-qualification status. The regular supply of ARV drugs, their appropriate storage and use and the monitoring of drug security are three essential prerequisites for success of ARV treatment units.

Drug Procurement and distribution:

First line ART:

Each ART facility in Malawi is designated in a particular category, based on size of facility, area of population served, HIV-prevalence rate in the population (if known) and TB case burden (as a proxy for AIDS cases). Facilities can also be upgraded or downgraded depending on performance.

<table>
<thead>
<tr>
<th>Burden Level</th>
<th>Patients Placed on ART in a Month</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low Burden</td>
<td>25 new patients</td>
</tr>
<tr>
<td>Medium Burden</td>
<td>50 new patients</td>
</tr>
<tr>
<td>Medium/High Burden</td>
<td>100 new patients</td>
</tr>
<tr>
<td>High Burden</td>
<td>150 new patients</td>
</tr>
<tr>
<td>Very High Burden</td>
<td>250 new patients</td>
</tr>
<tr>
<td>Super High Burden</td>
<td>400 new patients</td>
</tr>
</tbody>
</table>

The HIV Unit orders first line ARV drugs for each facility for 6 months. The drug orders are calculated for a) the number of new patients to start ART in the 6-month period, based on the category of the facility, b) the number of patients already placed on ART and alive and taking drugs from the facility and c) the drug stocks in the pharmacy. Drugs are ordered as “Starter Pack kits” and “Continuation Pack kits”.

A starter pack kit contains antiretroviral drugs to start 75 new patients on treatment, and is based on a low burden unit starting 25 new patients every month for 3 months. A continuation pack kit contains antiretroviral drugs to maintain these 75 patients on treatment for 3 months. The composition of these kits is shown in the Table below.
**Table: Starter pack kits and continuation pack kits**

<table>
<thead>
<tr>
<th>Starter pack kit</th>
<th>Continuation pack kit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provides drugs for 75 new patients starting ART for 14 days</td>
<td>Provides drugs for 75 patients to continue on ART for 3 months, and receiving drug tins every 28 days</td>
</tr>
<tr>
<td><strong>150 tins of ART:</strong></td>
<td><strong>225 tins of ART</strong></td>
</tr>
<tr>
<td>75 tins of d4T-30mg/ 3TC (15 tablets)</td>
<td>225 tins of d4T-30mg/ 3TC/ NVP (60 tablets)</td>
</tr>
<tr>
<td>75 tins of d4T-30mg/ 3TC/ NVP (15 tablets)</td>
<td></td>
</tr>
</tbody>
</table>

In its first six-month period a low burden facility needs 2 starter pack kits (1 for each quarter) and 3 continuation pack kits (1 for the first three months and 2 for the next three months to cater for those placed on treatment in the first quarter and those coming on to treatment in the second quarter). A medium burden unit in its first six months needs 4 starter pack kits and 6 continuation pack kits, while a high burden unit needs 12 starter pack kits and 18 continuation pack kits.

*Alternative first line ART and second line ART:*

These drugs used to be supplied to central hospitals and to experienced district hospitals. However, this has now changed and all ART facilities now receive alternative first line ART. Second-line ART is supplied to all central hospitals, selected district hospitals and a few private hospitals.

**Drug Security:**

Once the drugs have arrived at the hospital (or in later years at the health centre) there has to be a robust system of ensuring that patient consumption matches drug usage (see Table). Otherwise, there may be leakage of ARV drugs out of the hospital.

**Table: Drug security**

| Drug consumption by patients = drug usage from the treatment unit |

Drug security is checked every quarter during the routine supervisory visits. Most ART clinic facilities use an [ARV Drug Register](#) to record drugs given to patients and this is checked during supervisory visits.
Drug formulations needed for Malawi

The drug formulations used in Malawi are shown in the Table below.

**Table: Current drug formulations, with examples of trade names, for Malawi:**

<table>
<thead>
<tr>
<th>Drug Formulation</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>D4T/3TC/NVP ( stavudine-30 mg formulations)</td>
<td>15 and 60 tabs</td>
</tr>
<tr>
<td>D4T/3TC (stavudine-30mg formulations)</td>
<td>15 and 60 tabs</td>
</tr>
<tr>
<td>AZT/3TC (dual combination “Duovir”)</td>
<td>60 tabs</td>
</tr>
<tr>
<td>EFV</td>
<td>30 tabs</td>
</tr>
<tr>
<td>ABC</td>
<td>60 tabs</td>
</tr>
<tr>
<td>ddI-EC (enteric coated)</td>
<td>30 capsules</td>
</tr>
<tr>
<td>NVP</td>
<td>60 tabs</td>
</tr>
<tr>
<td>3TC</td>
<td>60 tablets</td>
</tr>
<tr>
<td>Tenofovir (TDF, “Viread”)</td>
<td>30 tabs</td>
</tr>
<tr>
<td>Lopinavir/Ritonavir (LPV/r, “Aluvia”)</td>
<td>120 tablets</td>
</tr>
</tbody>
</table>

Consideration is being given to other regimens for future use, and these are listed in the Table

**Table: Future drug formulations, with examples of trade names, which may be used in Malawi:**

<table>
<thead>
<tr>
<th>Drug Formulation</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>TDF/3TC/EFV (triple combination, “Atripla”)</td>
<td>60 tablets</td>
</tr>
<tr>
<td>Atazanavir/Ritonavir (ATZ/r)</td>
<td>60 tablets</td>
</tr>
</tbody>
</table>
TRAINING IN USE OF ART

Background:

It is essential that staff who are to manage patients with ART are well trained. The core material for the modules will be the “ARV Treatment Guidelines” and “the Management of HIV-related diseases”.

Training:

There will be two types of training:-

a) Pre-service training.
Medical students, paramedical students and nursing students will all undergo a modular training in use of ART and management of opportunistic infections. These modules have been developed and have been integrated into the curricula of the various training institutions. If these students qualify from the training institutions, they will be considered to have been trained in ART

b) In-service training.
All staff in the public sector who deliver ART, and who have not been trained in the pre-service years, must undertake the formal 5-day ART and HIV-related diseases training course and pass the formal examination. For those who are going to deliver ART, it is expected that they do a formal attachment at one of the experienced clinical centres or at their own facility once experience has been developed. Refresher ART training courses will be run on an annual basis for these in-service staff.

Certification in the use of ART:

A formal certificate, signed by the Secretary for Health, is given to every staff member who has completed the in-service ART course and passed the examination. This certification is recognised with the Medical Council of Malawi and the Nurses and Midwives Council of Malawi. At the end of every training course, the names and addresses of those who have passed the examination are passed to the two regulatory bodies.

ART AND PRIVATE PRACTITIONERS

Private practitioners are a valuable part of the health delivery system in Malawi. The government sector is working with private practitioners to ensure that ARV drug regimens, systems of delivering ARV drugs, monitoring and evaluation are standardised throughout the country and are the same as in the public sector.

One of the pre-requisites of being able to prescribe subsidised ARV drugs is that the private health care worker should have a) undergone a formal training course in ART and b) be formally certified as competent in managing ART. This opportunity for training and certification is available for health care workers in the private sector in the same way as for the public sector. Training courses are done quarterly at the weekend for 2 days.
SUGGESTIONS FOR FURTHER READING

International references:

Bartlett JG, Gallant JE. Medical Management of HIV Infection. 2004 Edition. Johns Hopkins School of Medicine, Baltimore, USA. ISB Number 0-9755326-0X (new versions come out each year)


National References:


## ANNEX 1: TARGETS FOR ART SCALE UP

<table>
<thead>
<tr>
<th>Strategy Indicator</th>
<th>Baseline (End 2005)</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Input Indicators:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Up to date ART Manual Which is in circulation</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Number of districts providing ART (cumulative)</td>
<td>28</td>
<td>30</td>
<td>30</td>
<td>30</td>
<td>30</td>
<td>30</td>
</tr>
<tr>
<td>Number of public health facilities providing ART (cum)</td>
<td>60</td>
<td>90</td>
<td>90</td>
<td>110</td>
<td>120</td>
<td>120</td>
</tr>
<tr>
<td>Number of private health facilities providing ART (cum)</td>
<td>30</td>
<td>40</td>
<td>50</td>
<td>60</td>
<td>70</td>
<td>80</td>
</tr>
<tr>
<td>Number of public HCW trained and accredited in ART (cum)</td>
<td>1000</td>
<td>1400</td>
<td>1800</td>
<td>2200</td>
<td>2600</td>
<td>3000</td>
</tr>
<tr>
<td>Number of private HCW trained and accredited in ART (cum)</td>
<td>200</td>
<td>300</td>
<td>400</td>
<td>450</td>
<td>500</td>
<td>550</td>
</tr>
<tr>
<td>Number of facilities with stock-outs of ARV drugs</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Output Indicators:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of new patients started on ART each year</td>
<td>20,000</td>
<td>35,000</td>
<td>40,000</td>
<td>45,000</td>
<td>45,000</td>
<td>45,000</td>
</tr>
<tr>
<td>Number of new children started on ART each year</td>
<td>1,000 (5%)</td>
<td>2,625 (7.5%)</td>
<td>4,000 (10%)</td>
<td>4,500 (10%)</td>
<td>4,500 (10%)</td>
<td>4,500 (10%)</td>
</tr>
<tr>
<td>Number of patients ever started on ART by end of year (cum)</td>
<td>35,000</td>
<td>70,000</td>
<td>110,000</td>
<td>155,000</td>
<td>200,000</td>
<td>245,000</td>
</tr>
<tr>
<td>Number of children ever started on ART by end of year (cum)</td>
<td>1,750 (5%)</td>
<td>4,375 (6.25%)</td>
<td>8,375 (7.6%)</td>
<td>12,875 (8.3%)</td>
<td>17,375 (8.7%)</td>
<td>21,875 (8.9%)</td>
</tr>
<tr>
<td>Number who are alive and on ART at end of each year (cum)</td>
<td>30,000</td>
<td>60,000</td>
<td>90,000</td>
<td>130,000</td>
<td>170,000</td>
<td>208,000</td>
</tr>
<tr>
<td>Proportion of those ever started who have died (cum)</td>
<td>8%</td>
<td>12%</td>
<td>12%</td>
<td>17%</td>
<td>17%</td>
<td>17%</td>
</tr>
<tr>
<td>Proportion of those ever started who are lost to follow-up (cum)</td>
<td>8%</td>
<td>10%</td>
<td>10%</td>
<td>10%</td>
<td>10%</td>
<td>10%</td>
</tr>
<tr>
<td>Proportion of patients alive who are ambulatory (cum)</td>
<td>85%</td>
<td>85%</td>
<td>85%</td>
<td>85%</td>
<td>85%</td>
<td>85%</td>
</tr>
<tr>
<td>Proportion of patients alive who are at work (cum)</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
</tr>
<tr>
<td>Proportion of patients alive with 95% drug adherence (cum)</td>
<td>90%</td>
<td>90%</td>
<td>90%</td>
<td>90%</td>
<td>90%</td>
<td>90%</td>
</tr>
</tbody>
</table>
ANNEX 2a: DOSAGE GUIDELINES FOR FIRST LINE ART IN CHILDREN LESS THAN 10KG BODYWEIGHT (Triomune baby)\(^1\)

Lamivir S baby 30 (LamS baby): 6mg d4T/30mg 3TC; Triomune baby 30 (Trio baby): 6mg d4T/30mg 3TC/50mg NVP

**Target dosages:** d4T: 2mg/kg/d; 3TC: 8mg/kg/d; NVP: 120mg/m2/d OD (starter phase), 300-400mg/m2/d

### Starter Phase (First two weeks) Triomune baby

<table>
<thead>
<tr>
<th>body weight (kg)</th>
<th>Dose LamivirS baby</th>
<th>Dose Triomune baby</th>
<th>d4T dose (mg/d)</th>
<th>3TC dose (mg/d)</th>
<th>NVP dose mg/d</th>
<th>prepacked pills for 15 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>min max</td>
<td>am pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 3 5.99</td>
<td>1 1</td>
<td>12</td>
<td>60</td>
<td>50</td>
<td>15</td>
<td>15</td>
</tr>
<tr>
<td>2 6 9.99</td>
<td>1.5 1.5</td>
<td>18</td>
<td>90</td>
<td>75</td>
<td>23</td>
<td>23</td>
</tr>
</tbody>
</table>

### Continuation Phase Triomune baby

<table>
<thead>
<tr>
<th>body weight (kg)</th>
<th>Dose Trio baby</th>
<th>Dose Trio baby</th>
<th>d4T dose (mg/d)</th>
<th>3TC dose (mg/d)</th>
<th>NVP dose mg/d</th>
<th>pre-packed pills incl. 4 doses extra</th>
<th>Max remaining pills for &gt;95% adherence</th>
<th>pre-packed pills incl. 4 doses extra</th>
<th>Max remaining pills for &gt;95% adherence</th>
</tr>
</thead>
<tbody>
<tr>
<td>min max</td>
<td>am pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 3 5.99</td>
<td>1 1</td>
<td>12</td>
<td>60</td>
<td>100</td>
<td>60</td>
<td>7</td>
<td>116</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>2 6 9.99</td>
<td>1.5 1.5</td>
<td>18</td>
<td>90</td>
<td>150</td>
<td>90</td>
<td>10</td>
<td>174</td>
<td>14</td>
<td></td>
</tr>
</tbody>
</table>

\(^1\) Pre-packing and Pill count: Starter- and continuation packs can be pre-pack using the number of tablets given in the tables. Adherence can be assessed by comparing remaining tablets with the number of remaining tablets for 95% adherence (continuation phase). Appointments can be adjusted according to remaining tablets in the bottle and the new supply.
ANNEX 2b: DOSAGE GUIDELINES FOR FIRST LINE ART IN CHILDREN for children less than 10kg if Triomune baby is not available and for children 10kg and above (split adult T30 regimen)²,³,⁴

<table>
<thead>
<tr>
<th>body weight (kg)</th>
<th>Dose T30 pm</th>
<th>Dose LamS30 am</th>
<th>d4T dose (mg/d)</th>
<th>3TC dose (mg/d)</th>
<th>NVP dose (mg/d)</th>
<th>pre-packed pills for 15 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>min</td>
<td>max</td>
<td>T30</td>
<td>LamS 30</td>
<td>T30</td>
<td>LamS 30</td>
<td>T30</td>
</tr>
<tr>
<td>1</td>
<td>3</td>
<td>4,99</td>
<td>0,25</td>
<td>7,5</td>
<td>37,5</td>
<td>50</td>
</tr>
<tr>
<td>2</td>
<td>5</td>
<td>7,99</td>
<td>0,25</td>
<td>0,25</td>
<td>15</td>
<td>75</td>
</tr>
<tr>
<td>3</td>
<td>8</td>
<td>11,99</td>
<td>0,25</td>
<td>0,25</td>
<td>15</td>
<td>75</td>
</tr>
<tr>
<td>4</td>
<td>12</td>
<td>13,99</td>
<td>0,5</td>
<td>0,5</td>
<td>30</td>
<td>150</td>
</tr>
<tr>
<td>5</td>
<td>14</td>
<td>18,99</td>
<td>0,5</td>
<td>0,75</td>
<td>37,5</td>
<td>187,5</td>
</tr>
<tr>
<td>6</td>
<td>19</td>
<td>25,99</td>
<td>0,75</td>
<td>0,75</td>
<td>45</td>
<td>225</td>
</tr>
<tr>
<td>7</td>
<td>26</td>
<td>29,99</td>
<td>0,75</td>
<td>1</td>
<td>52,5</td>
<td>262,5</td>
</tr>
<tr>
<td>8</td>
<td>30</td>
<td>30</td>
<td>1</td>
<td>1</td>
<td>60</td>
<td>300</td>
</tr>
</tbody>
</table>

² Cutting of tablets: Since T30 tablets are not scored, the use of commercial tablets cutters, provided by the HIV unit, is recommended.
³ Dose of T30: 0,25= ¼ tablet T30; 0,5= ½ tablet T30, 0,75= ¾ tablet T30.
⁴ Pre-cutting of tablets: Particularly quartered tablets are not firm, and may break down over time. Therefore, pre-cutting of tablets is discouraged.
<table>
<thead>
<tr>
<th>body weight (kg)</th>
<th>Dose T30 am</th>
<th>Dose T30 am</th>
<th>d4T dose (mg/d)</th>
<th>3TC dose (mg/d)</th>
<th>NVP dose mg/d</th>
<th>pre-packed pills incl. 6 doses extra</th>
<th>Max remaining pills for &gt;95% adherence</th>
<th>pre-packed pills incl. 6 doses extra</th>
<th>Max remaining pills for &gt;95% adherence</th>
</tr>
</thead>
<tbody>
<tr>
<td>min</td>
<td>max</td>
<td>am</td>
<td>pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>3</td>
<td>4.99</td>
<td>0.25</td>
<td>15</td>
<td>37.5</td>
<td>50</td>
<td>9</td>
<td>2</td>
<td>16</td>
</tr>
<tr>
<td>2</td>
<td>5</td>
<td>7.99</td>
<td>0.25 0.25</td>
<td>22.5</td>
<td>112.5</td>
<td>150</td>
<td>24</td>
<td>4</td>
<td>45</td>
</tr>
<tr>
<td>3</td>
<td>8</td>
<td>11.99</td>
<td>0.25</td>
<td>20</td>
<td>150</td>
<td>200</td>
<td>31</td>
<td>4</td>
<td>59</td>
</tr>
<tr>
<td>4</td>
<td>12</td>
<td>13.99</td>
<td>0.5</td>
<td>37.5</td>
<td>187.5</td>
<td>250</td>
<td>40</td>
<td>6</td>
<td>75</td>
</tr>
<tr>
<td>5</td>
<td>14</td>
<td>18.99</td>
<td>0.75 0.5</td>
<td>45</td>
<td>225</td>
<td>300</td>
<td>47</td>
<td>7</td>
<td>89</td>
</tr>
<tr>
<td>6</td>
<td>19</td>
<td>25.99</td>
<td>0.75</td>
<td>52.5</td>
<td>262.5</td>
<td>350</td>
<td>55</td>
<td>8</td>
<td>104</td>
</tr>
<tr>
<td>7</td>
<td>26</td>
<td>29.99</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>≥30</td>
<td>1</td>
<td>1</td>
<td>60</td>
<td>300</td>
<td>400</td>
<td>60</td>
<td>7</td>
<td>118</td>
</tr>
</tbody>
</table>

Continuation Phase MW paediatric split T30 regimen

<table>
<thead>
<tr>
<th>min</th>
<th>max</th>
<th>am</th>
<th>pm</th>
<th>d4T dose (mg/d)</th>
<th>3TC dose (mg/d)</th>
<th>NVP dose mg/d</th>
<th>pre-packed pills incl. 6 doses extra</th>
<th>Max remaining pills for &gt;95% adherence</th>
<th>pre-packed pills incl. 6 doses extra</th>
<th>Max remaining pills for &gt;95% adherence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3</td>
<td>4.99</td>
<td>0.25</td>
<td>15</td>
<td>37.5</td>
<td>50</td>
<td>9</td>
<td>2</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>5</td>
<td>7.99</td>
<td>0.25 0.25</td>
<td>22.5</td>
<td>112.5</td>
<td>150</td>
<td>24</td>
<td>4</td>
<td>45</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>8</td>
<td>11.99</td>
<td>0.25</td>
<td>20</td>
<td>150</td>
<td>200</td>
<td>31</td>
<td>4</td>
<td>59</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>12</td>
<td>13.99</td>
<td>0.5</td>
<td>37.5</td>
<td>187.5</td>
<td>250</td>
<td>40</td>
<td>6</td>
<td>75</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>14</td>
<td>18.99</td>
<td>0.75 0.5</td>
<td>45</td>
<td>225</td>
<td>300</td>
<td>47</td>
<td>7</td>
<td>89</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>19</td>
<td>25.99</td>
<td>0.75</td>
<td>52.5</td>
<td>262.5</td>
<td>350</td>
<td>55</td>
<td>8</td>
<td>104</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>26</td>
<td>29.99</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>≥30</td>
<td>1</td>
<td>1</td>
<td>60</td>
<td>300</td>
<td>400</td>
<td>60</td>
<td>7</td>
<td>118</td>
<td></td>
</tr>
</tbody>
</table>
ANNEX 3: DOSAGE GUIDELINES FOR ALTERNATIVE FIRST LINE ART AND SECOND LINE ART FOR CHILDREN

Alternative 1st line for children for NVP related cutaneous reactions and hepatotoxicity⁵ ⁶ ⁷

<table>
<thead>
<tr>
<th>body weight (kg)</th>
<th>d4T30mg/3TC150 mg tablets</th>
<th>EFV 600mg tablets</th>
<th>d4T dose (mg/d)</th>
<th>3TC dosage dose (mg/d)</th>
<th>EFV dose (mg/d)</th>
<th>1 months supply</th>
<th>2 months supply</th>
</tr>
</thead>
<tbody>
<tr>
<td>min max</td>
<td>am pm</td>
<td>am pm</td>
<td>am pm</td>
<td>am pm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 10</td>
<td>11,99</td>
<td>0,50</td>
<td>0,25</td>
<td>none</td>
<td>0,33</td>
<td>22,5</td>
<td>112,5</td>
</tr>
<tr>
<td>2 12</td>
<td>13,99</td>
<td>0,50</td>
<td>0,50</td>
<td>none</td>
<td>0,33</td>
<td>30</td>
<td>150</td>
</tr>
<tr>
<td>3 14</td>
<td>18,99</td>
<td>0,75</td>
<td>0,50</td>
<td>none</td>
<td>0,33</td>
<td>37,5</td>
<td>187,5</td>
</tr>
<tr>
<td>4 19</td>
<td>25,99</td>
<td>0,75</td>
<td>0,75</td>
<td>none</td>
<td>0,50</td>
<td>45</td>
<td>225</td>
</tr>
<tr>
<td>5 26</td>
<td>29,99</td>
<td>1,00</td>
<td>0,75</td>
<td>none</td>
<td>0,66</td>
<td>52,5</td>
<td>262,5</td>
</tr>
<tr>
<td>6 30</td>
<td>39,99</td>
<td>1,00</td>
<td>0,00</td>
<td>none</td>
<td>0,66</td>
<td>60</td>
<td>300</td>
</tr>
<tr>
<td>7 40</td>
<td>60,00</td>
<td>1,00</td>
<td>1,00</td>
<td>none</td>
<td>1,00</td>
<td>60</td>
<td>300</td>
</tr>
</tbody>
</table>

⁵ EFV is not licensed for children <3 years and <10kg.
⁶ Dosage of EFV: 0,33= 1/3 tablet of EFV; 0,50= ½ tablet of EFV; 0,66= 2/3 tablet of EFV. Cutting of EFV in 1/3 or 2/3 is particularly challenging. It is recommended to mark the tablets and thereafter to cut with a sharp knife. No pre-cutting of tablets.
⁷ There are no PK data on the use of split EFV 600mg tablets.
ANNEX 3: Alternative 1st line for children for peripheral neuropathy8,9,10

<table>
<thead>
<tr>
<th>body weight (kg)</th>
<th>AZT300mg/3TC150 mg tablets</th>
<th>NVP 200mg tablets</th>
<th>AZT dose (mg/d)</th>
<th>3TC dosage dose (mg/d)</th>
<th>NVP dose (mg/d)</th>
<th>1 months supply</th>
<th>2 months supply</th>
</tr>
</thead>
<tbody>
<tr>
<td>min</td>
<td>max</td>
<td>am</td>
<td>pm</td>
<td>am</td>
<td>pm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>8</td>
<td>9,9</td>
<td>0,25</td>
<td>0,25</td>
<td>150</td>
<td>75</td>
<td>150</td>
</tr>
<tr>
<td>2</td>
<td>10</td>
<td>14,99</td>
<td>0,50</td>
<td>0,25</td>
<td>225</td>
<td>112,5</td>
<td>200</td>
</tr>
<tr>
<td>3</td>
<td>15</td>
<td>19,99</td>
<td>0,50</td>
<td>0,50</td>
<td>300</td>
<td>150</td>
<td>250</td>
</tr>
<tr>
<td>4</td>
<td>20</td>
<td>24,99</td>
<td>0,75</td>
<td>0,75</td>
<td>450</td>
<td>225</td>
<td>350</td>
</tr>
<tr>
<td>5</td>
<td>25</td>
<td>29,99</td>
<td>0,75</td>
<td>1,00</td>
<td>525</td>
<td>262,5</td>
<td>400</td>
</tr>
<tr>
<td>6</td>
<td>30</td>
<td>34,99</td>
<td>1,00</td>
<td>1,00</td>
<td>600</td>
<td>300</td>
<td>400</td>
</tr>
<tr>
<td>7</td>
<td>35</td>
<td>60,00</td>
<td>1,00</td>
<td>1,00</td>
<td>600</td>
<td>300</td>
<td>400</td>
</tr>
</tbody>
</table>

8 Cutting of tablets: Since AZT/3TC and NVP tablets are not scored up to quarters, the use of commercial tablets cutters, provided by the HIV unit, is recommended. Pre-cutting of tablets is discouraged.
9 There are no PK data for split AZT/3TC.
10 The dosage guidelines for AZT/3TC can also be used for PeP in children. AZT should not be started if Hb <8g/dl
### ANNEX 3: Second Line Treatment for children

<table>
<thead>
<tr>
<th>Body weight (kg)</th>
<th>Paediatric 2nd line regimen</th>
<th>1 months supply</th>
<th>2 months supply</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ABC 300mg tablets</td>
<td>ddl EC 125mg, ddl 200mg EC capsules</td>
<td>ABC pre-packed pills incl. 4 doses extra</td>
</tr>
<tr>
<td>min max</td>
<td>dosage (mg/d)</td>
<td>dosage (mg/d)</td>
<td>dosage (mg/d)</td>
</tr>
<tr>
<td>1 10 11.99</td>
<td>0.50 0.25 125 none 1.0 0.5 225 125 300</td>
<td>23 32 none 46 44 60 none 88</td>
<td>60</td>
</tr>
<tr>
<td>2 12 14.99</td>
<td>0.50 0.25 125 none 1.0 0.5 225 125 300</td>
<td>23 32 none 46 44 60 none 88</td>
<td>60</td>
</tr>
<tr>
<td>3 15 19.99</td>
<td>0.50 0.50 200 none 1.0 0.5 300 200 300</td>
<td>30 none 32.00 46 58 none 60.00 88</td>
<td>60</td>
</tr>
<tr>
<td>4 20 24.99</td>
<td>0.75 0.50 200 none 1.5 1.0 375 200 500</td>
<td>38 none 32.00 76 73 none 60.00 146</td>
<td>60</td>
</tr>
<tr>
<td>5 25 29.99</td>
<td>0.75 0.75 250 none 1.5 1.5 450 250 600</td>
<td>45 60 none 90 87 120 none 174</td>
<td>60</td>
</tr>
<tr>
<td>6 30 34.99</td>
<td>1.00 0.75 250 none 1.5 1.5 525 250 600</td>
<td>53 60 none 90 102 120 none 174</td>
<td>60</td>
</tr>
<tr>
<td>7 35 44.99</td>
<td>1.00 1.00 325 none 2.0 1.5 600 325 700</td>
<td>60 32 32.00 106 116 60 60.00 204</td>
<td>60</td>
</tr>
<tr>
<td>8 45 49.99</td>
<td>1.00 1.00 325 none 2.0 2.0 600 325 800</td>
<td>60 32 32.00 120 116 60 60.00 232</td>
<td>60</td>
</tr>
<tr>
<td>9 50 59.99</td>
<td>1.00 1.00 400 none 2.0 2.0 600 400 800</td>
<td>60 none 60.00 120 116 none 120.00 232</td>
<td>60</td>
</tr>
</tbody>
</table>
ANNEX 4: NEW PATIENT MASTER CARD FOR ART [front]: ART Number ________________ Year ________________

Name __________________________ Age _____ Sex _____ Initial Wt (Kg)_______ Initial Ht (cm)______ Transfer-In (Y/N)_____

Address (physical address and phone)_________________________________________________________ Follow-up agreement (Y/N)_____

Name of identifiable guardian_________________________________________________________ Date and place of positive HIV test____________________________

Date of starting 1st line ARV regimen _____________ Reason for ARV: Stage ___________; PTB____; EPTB____; KS_____; PMTCT____

Date of starting alternative 1st line ARV regimen (specify) ________________ Date of starting 2nd line ARV regimen (specify)_________________

<table>
<thead>
<tr>
<th>Month</th>
<th>Date</th>
<th>Wt Kg</th>
<th>Ht cm</th>
<th>Outcome status</th>
<th>Of those alive</th>
<th>Ambulatory</th>
<th>Work/school</th>
<th>Side effects</th>
<th>No. Pills in Bottle</th>
<th>ARV Given</th>
<th>CPT</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>A  D  DF  Stop</td>
<td>Start</td>
<td>Sbs</td>
<td>Switch</td>
<td>Amb</td>
<td>Bed</td>
<td>Yes</td>
<td>No</td>
<td>Y</td>
</tr>
<tr>
<td>Jan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feb</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mar</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apr</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>May</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jun</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jul</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aug</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sep</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oct</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nov</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dec</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Specify reason for ART (Stage III, Stage IV, CD4 < 250, PTB, EPTB, Transfer-in)
Outcome status: A = alive; D = dead; DF = defaulted and not seen for 3 months; Stop = stopped medication; TO = transferred out to another unit
Of those alive: Start = alive and on first line regimen; Sbs = alive and substituted to alternative first line regimen; Switch = alive and switched to a second line regimen because of failure of first line regimen
Ambulatory: Amb = able to walk to/at treatment unit and walks at home unaided; Bed = most of time in bed at home
Work/school: Yes = engaged in previous work/employment or at school; No = not engaged in previous work/employment or not at school
Side effects: If Yes, specify – PN = peripheral neuropathy; HP = hepatitis; SK = skin rash; LA = lactic acidosis; LD = lipodystrophy; AN = anaemia
No. Pills in bottle: if patient comes at 4 weeks count number of pills in bottle (8 pills or less = 95% adherent)
ARV given P = patient; G = guardian. Indicate the number of tins of ART given to patient or guardian
CPT: indicate if patient on cotrimoxazole preventive therapy: Blank column for remarks
ANNEX 4: NEW PATIENT MASTER CARD FOR ARV  [back]: Clinical Record Form

Indicate in the columns below what disease(s) the patients has by placing a ring around the bullet point next to the disease or clinical problem

<table>
<thead>
<tr>
<th>WHO Clinical Stage I</th>
<th>WHO Clinical Stage II</th>
<th>WHO Clinical Stage III</th>
<th>WHO Clinical Stage IV</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>For adults and children</strong></td>
<td><strong>For adults</strong></td>
<td><strong>For adults and children</strong></td>
<td><strong>For adults and children</strong></td>
</tr>
<tr>
<td>• Asymptomatic</td>
<td>• Unintentional weight loss &lt; 10% of body weight in the absence of concurrent illness</td>
<td>• Oral candidiasis</td>
<td>• HIV wasting syndrome (weight loss &gt; 10% of body weight and either chronic fever or diarrhoea in the absence of concurrent illness)</td>
</tr>
<tr>
<td>• Persistent Generalised lymphadenopathy</td>
<td>• Minor mucocutaneous manifestations (seborrhic dermatitis, prurigo, fungal nail infections, recurrent oral ulcerations, angular cheilitis)</td>
<td>• Oral hairy leukoplakia</td>
<td>• Pneumocystis carinii pneumonia</td>
</tr>
<tr>
<td></td>
<td>• Herpes zoster</td>
<td>• Unintentional weight loss &gt; 10% of body weight in the absence of concurrent illness</td>
<td>• Toxoplasmosis of the brain</td>
</tr>
<tr>
<td></td>
<td>• Recurrent upper respiratory tract infections (ie, bacterial sinusitis)</td>
<td>• Chronic diarrhoea &gt; 1 month</td>
<td>• Cryptosporidiosis or Isosporiasis</td>
</tr>
<tr>
<td><strong>For children</strong></td>
<td></td>
<td>• Prolonged fever (intermittent or constant) &gt; 1 month</td>
<td>• Recurrent severe presumed pneumonia</td>
</tr>
<tr>
<td>• Unexplained persistent hepatomegaly and splenomegaly</td>
<td></td>
<td>• Active Pulmonary Tuberculosis</td>
<td>• Cryptococcosis, extrapulmonary</td>
</tr>
<tr>
<td>• Papular itchy skin eruptions</td>
<td></td>
<td>• PTB within the past 2 years</td>
<td>• Cytomegalovirus of an organ other than liver, spleen or lymph node</td>
</tr>
<tr>
<td>• Extensive wart virus infection</td>
<td></td>
<td>• Severe bacterial infections (eg pneumonia, pyomyositis, sepsis)</td>
<td>• Herpes simplex infection, mucocutaneous for &gt; 1 month or visceral</td>
</tr>
<tr>
<td>• Extensive molluscum contagiosum</td>
<td></td>
<td>• Acute ulcerative mouth infections</td>
<td>• Progressive multifocal leucoencephalopathy</td>
</tr>
<tr>
<td>• Recurrent oral ulcerations</td>
<td></td>
<td>• Unexplained anaemia, neutropenia or thrombocytopenia</td>
<td>• Any disseminated endemic mycosis</td>
</tr>
<tr>
<td>• Unexplained persistent parotid gland enlargement</td>
<td></td>
<td>• Additional for children</td>
<td>• Candidiasis of oesophagus / trachea / bronchus</td>
</tr>
<tr>
<td>• Linear gingival erythema</td>
<td>• Moderate unexplained malnutrition</td>
<td>• Atypical mycobacteriosis, disseminated or lung</td>
<td>• Atypical mycobacteriosis, disseminated or lung</td>
</tr>
<tr>
<td>• Herpes zoster</td>
<td>• TB lymphadenopathy</td>
<td>• Recurrent bacteraemia or sepsis with NTS</td>
<td>• Recurrent bacteraemia or sepsis with NTS</td>
</tr>
<tr>
<td>• Recurrent or chronic respiratory tract infections (sinusitis, otitis externa, tonsillitis, otitis media)</td>
<td>• Severe recurrent bacterial pneumonia</td>
<td>• Extrapulmonary tuberculosis (EPTB)</td>
<td>• Extrapulmonary tuberculosis (EPTB)</td>
</tr>
<tr>
<td>• Fungal nail infections</td>
<td>• Symptomatic lymphoid interstitial pneumonia</td>
<td>• Lymphoma (cerebral or B-cell Non Hodgkin)</td>
<td>• Lymphoma (cerebral or B-cell Non Hodgkin)</td>
</tr>
<tr>
<td></td>
<td>• Chronic HIV lung disease, including bronchiectasis</td>
<td>• Kaposi’s sarcoma</td>
<td>• Kaposi’s sarcoma</td>
</tr>
<tr>
<td></td>
<td>• HIV-associated cardiomyopathy</td>
<td>• HIV encephalopathy</td>
<td>• HIV encephalopathy</td>
</tr>
<tr>
<td></td>
<td>• HIV-associated nephropathy</td>
<td>• Other (Cancer cervix, visceral leishmaniasis)</td>
<td>• Other (Cancer cervix, visceral leishmaniasis)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• HIV-associated cardiomyopathy (adults only)</td>
<td>• HIV-associated cardiomyopathy (adults only)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• HIV-associated nephropathy (adults only)</td>
<td>• HIV-associated nephropathy (adults only)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Additional for children</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Unexplained severe wasting, stunting or malnutrition not responding to treatment</td>
<td>• Unexplained severe wasting, stunting or malnutrition not responding to treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Recurrent severe presumed bacterial infections (eg empyema, sepsis, meningitis, bone or joint)</td>
<td>• Recurrent severe presumed bacterial infections (eg empyema, sepsis, meningitis, bone or joint)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• EPTB but excluding TB lymphadenopathy</td>
<td>• EPTB but excluding TB lymphadenopathy</td>
</tr>
</tbody>
</table>
ANNEX 4: FOLLOW UP PATIENT MASTER CARD FOR ARV [front and back are similar]:
Name___________________________________________ ARV Number___________________________

<table>
<thead>
<tr>
<th>Year</th>
<th>Outcome status</th>
<th>Of those alive</th>
<th>ARV Given</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>P G</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Month</th>
<th>Date</th>
<th>Wt Kg</th>
<th>Ht cm</th>
<th>Outcome status</th>
<th>Of those alive</th>
<th>Ambulatory</th>
<th>Work/school</th>
<th>Side effects</th>
<th>No. Pills in Bottle</th>
<th>ARV Given</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>A D DF Stop TO Start Sbs Switch Amb Bed Yes No Y N</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feb</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mar</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apr</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>May</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jun</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jul</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aug</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sep</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oct</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nov</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dec</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ANNEX 5: PATIENT ART REGISTER [left hand page]

<table>
<thead>
<tr>
<th>ART Registration Number</th>
<th>Year</th>
<th>Quarter</th>
<th>Date of registration</th>
<th>Name</th>
<th>Sex</th>
<th>Age</th>
<th>Address</th>
<th>Date first started ARV drugs</th>
<th>Reason for starting ARV drugs</th>
<th>Name / address of Guardian</th>
<th>ARVT Treatment Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Reason for starting ARV Drugs: Stage III, Stage IV, CD4 count < 250/mm³, Stage II with TLC < 1200/mm³
Also indicate under Reasons for ART – PTB, EPTB, KS and Transfer In (TI)*

*Quarters: 1 = January to March: 2 = April to June: 3 = July to September: 4 = October - December*
**ANNEX 5: PATIENT ART REGISTER**

<table>
<thead>
<tr>
<th>Outcome (provide date when change from alive)</th>
<th>Of those alive (provide date when change from start)</th>
<th>Ambulant</th>
<th>At work or (in children) at school</th>
<th>Remarks (including occupation, BMI, ITN)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alive</td>
<td>Dead</td>
<td>Default</td>
<td>Stop</td>
<td>Transfer</td>
</tr>
<tr>
<td>Alive - alive and on ARV drugs</td>
<td>Dead - whatever the cause</td>
<td>Default</td>
<td>Stop</td>
<td>Transfer</td>
</tr>
<tr>
<td>Transfer - transfer-out to another ART treatment unit</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Start - on first line regimen</td>
<td>Substitute - changed to alternative first line regimen</td>
<td>Switch</td>
<td>Changed to second line regimen</td>
<td>Ambulant - yes/no</td>
</tr>
<tr>
<td>Alive - alive and on ARV drugs</td>
<td>Dead - whatever the cause</td>
<td>Default</td>
<td>Stop</td>
<td>Transfer</td>
</tr>
</tbody>
</table>
ANNEX 6: ARV PATIENT IDENTITY CARD

<table>
<thead>
<tr>
<th>ART IDENTITY CARD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current Treatment Unit_______________________</td>
</tr>
<tr>
<td>Name of Patient____________________________</td>
</tr>
<tr>
<td>Unique ARV Number___________________________</td>
</tr>
<tr>
<td>Age__  Sex__  Weight (Kg)____  Height (cm)___</td>
</tr>
<tr>
<td>Name of Guardian____________________________</td>
</tr>
<tr>
<td>Start  1st line ART (date) ____________</td>
</tr>
<tr>
<td>Reason for ART_____________________________</td>
</tr>
<tr>
<td>Start  alternative 1st line ART (date)______</td>
</tr>
<tr>
<td>Start  2nd line ART (date)_______________</td>
</tr>
</tbody>
</table>
ANNEX 7: COHORT ANALYSIS FORM [same data for quarterly and cumulative]

**Case Data:**

Number of patients started on ART in the last quarter________________________

Number of men started_________  Number of women started__________

Number of adults (15 and above)_______  Number of children (14 and below)_____

Occupation: Housewives_____  Farmers _____  Soldiers/Police______  Teachers_______

Business_____  Health care workers_____  Students/school____  Other_______________

Reasons for starting: Stage III_____  Stage IV_____  CD4 count____________

Indicate number started because of TB______ ( PTB_____  EPTB_____ Not known______)

Indicate number of pregnant women started on ART from PMTCT__________________

**Outcome Data:**

Number alive and on ART____________________________________________

(Number alive and on first line regimen (Start)__________________________)

(Number alive and on alternative first line regimen (Substituted)____________)

(Number alive and on second line regimen (Switch)_______________________)

Number who have died_____________________________________________

Number who have defaulted [no defaults in a quarterly analysis]___________

Number who have stopped___________________________________________

Number who have transferred out_____________________________________

Of the number alive and on ART:

Number who are ambulatory___________________________________________

Number who are at work____________________________________________

Number who have side effects________________________________________

Number adults on 1st line regimen with pill count done in last month of quarter____

Number with the pill count in the last month of the quarter at 8 or less_______

Of those who died:  Number in month 1______ Number in month 2______

Number in Month 3______ Number after month 3______
ANNEX 8: CUMULATIVE ANALYSIS - AN EXAMPLE

Case Data:

Total number of patients ever started on ART 200
Number of men started 50  Number of women started 150
Number of adults (15 and above) 180  Number of children (14 and below) 20
Occupation: Housewives 40  Farmers 50  Soldiers/Police 2  Teachers 10
Business 30  Health care workers 3  Students/school 10  Other 55
Reasons for starting: Stage III 140  Stage IV 50  CD4 count 10
Indicate number started because of TB 35  (PTB 30  EPTB 5  Not known 0)
Indicate number of pregnant women started on ART from PMTCT 5

Outcome Data:

Number alive and on ART 140
(Number alive and on first line regimen (Start) 130
(Number alive and on alternative first line regimen (Substituted) 10
(Number alive and on second line regimen (Switch) 0
Number who have died 30
Number who have defaulted 20
Number who have stopped 5
Number who have transferred out 5
Of the total number alive and on ART (140)
Number who are ambulatory 135
Number who are at work 130
Number who have side effects 25
Number adults on 1st line regimen with pill count done in last month of quarter 100
Number with the pill count in the last month of the quarter at 8 or less 90

Of those who died:
Number in month 1 (15)  Number in month 2 (5)
Number in Month 3 (5)  Number after month 3 (5)
ANNEX 9: **ART Supervision and Monitoring Check List**

Hospital_____________________________ Date________________________
Year________________________ Quarter evaluated__________

**ARV Clinic (orderly and tidy)**

**ARV Filing system in place**

**ARV Register:**

Registration numbers are correct and match the master card numbers
Transfer-in patients are registered with the next site registration number
Patient registration is a continuous process and not one month per page
All columns are filled in (age, sex, reason for ART, ambulatory, work)
Transfer-in patients recorded under “Reason for ART”
Dates of outcomes are properly recorded under outcome columns
Patients’ occupation is recorded in “Remarks”
If patient is pregnant and referred from PMTCT this is indicated in “Remarks”__
TB is indicated under “Reason for ART” – also PTB and EPTB
All ARV outcomes are updated every three months
ARV Register is up to date and in line with Master Cards

**ARV Master Cards:**

The case finding data is properly completed on each Patient Master Card
TB indicated “PTB or EPTB” under reason for ART next to Stage
The 2-week visit after the start of ART is written at the bottom of the card
Regular record of Weight done at every visit
Each monthly visit has all columns completed
Pill counts done according to previous directives
Back of master card is completed

**ARV Drug Register**

Being used
ART Cohort Analysis:

Cohort analysis done for the quarter____________________________________

Cohort analysis done for the cumulative number on ART_______________

Cohort outcomes are correct for quarter and cumulative analysis____

ART Clinic Days: Total number of days per week for ART clinic____

New patient days_____________ Follow-up patient days______________

Group Counselling (and check the time between GC and start of ART)____

On a clinic day, number clinicians____ number nurses______ number clerks____

VCT Register

Properly completed and monthly summaries done properly______________

Number tested in the quarter__________ Number HIV positive in the quarter_____

Number of people referred to ART in the quarter_____________________

Pharmacy:

<table>
<thead>
<tr>
<th>ARV Drugs</th>
<th>Tins in Last order</th>
<th>Number of Tins in stock</th>
</tr>
</thead>
<tbody>
<tr>
<td>D4T/3TC (D4T-30mg) [15 tablets]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D4T/3TC (D4T-40mg) [15 tablets]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D4T/3TC/NVP (D4T-30mg) [15 tablets]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D4T/3TC/NVP (D4T-40mg) [15 tablets]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D4T/3TC/NVP (D4T-30mg) [60 tablets]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D4T/3TC/NVP (D4T-40mg) [60 tablets]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>“Duovir” for PEP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AZT/3TC [60 tablets] – Alternative/2nd line</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nevirapine [60 tablets]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D4T/3TC-30/40 [60 tablets] – Alternative</td>
<td>D4T30= /d4T40=</td>
<td></td>
</tr>
<tr>
<td>Efavirenz [30 tablets] – Alternative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tenofovir [30 tablets]-2nd line</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaletra [180 capsules] 2nd line</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CPT (tins of 120 tablets)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTX (tins of 1000 or 500 tablets)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>OI Drugs</th>
<th>Number Tablets in stock</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluconazole (Diflucan programme)</td>
<td></td>
</tr>
<tr>
<td>Acyclovir</td>
<td></td>
</tr>
<tr>
<td>Ceftriaxone</td>
<td></td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td></td>
</tr>
<tr>
<td>Vincristine</td>
<td></td>
</tr>
<tr>
<td>Morphine</td>
<td></td>
</tr>
<tr>
<td>Amitryptiline</td>
<td></td>
</tr>
</tbody>
</table>

Laboratory:

CD4 Machine installed (specify yes/no and type)________________________
Quarterly ART Assessment: (assess for the quarter being evaluated)__________________

Case Data:
Number of patients started on ART in the last quarter________________________
Number of males started_______________  Number of females started_____________
Number of adults (15 and above)_______  Number of children (14 and below)____
Occupation: Housewives_____  Farmers_____  Soldiers/Police_____  Teachers_______
Business_____  Health care workers____  Students/school_____  Other_______________
Reasons for starting: Stage III_______   Stage IV_______  CD4 count_________________
Indicate number started because of TB_____ ( PTB_____  EPTB_____  Not known_____)
Indicate number of pregnant women started on ART from PMTCT___________________

Outcome Data:
Number alive and on ART____________________________________________
(Number alive and on first line regimen (Start)____________________________)
(Number alive and on alternative first line regimen (Substituted)_______________)
(Number alive and on second line regimen (Switch)_________________________)
Number who have died_______________________________________________
Number who have defaulted___________________________________________
Number who have stopped____________________________________________
Number who have transferred out_______________________________________
Of the number alive and on ART:
Number who are ambulatory___________________________________________
Number who are at work______________________________________________
Number who have side effects________________________________________
Number adults on 1st line regimen with pill count done in last month of quarter____
Number with the pill count in the last month of the quarter at 8 or less__________
Of those who died: Number in month 1_____ Number in month 2_____ Number in Month 3_____ Number after month 3____
Cumulative ART assessment: for patients registered up to __________________________

Case Data:
Total number of patients ever started on ART ______________________________
Number of males ____________ Number of females started ________________
Number of adults (15 and above) ___________ Number of children (14 and below) _____
Occupation: Housewives _____ Farmers _____ Soldiers/Police _____ Teachers ______
Business _____ Health care workers _____ Students/school _____ Other ___________
Reasons for starting: Stage III ______ Stage IV ______ CD4 count ______________
Indicate number started because of TB ______ ( PTB _____ EPTB _____ Not known _____)
Indicate number of pregnant women started on ART from PMTCT _________________

Outcome Data:
Number alive and on ART ________________________________
(Number alive and on first line regimen (Start)______________________________)
(Number alive and on alternative first line regimen (Substituted)__________)
(Number alive and on second line regimen (Switch)______________________)

Number who have died __________________________________________
Number who have defaulted _______________________________________
Number who have stopped _________________________________________
Number who have transferred out _________________________________

Of the total number alive and on ART:
Number who are ambulatory_______________________________________
Number who are at work________________________________________
Number who have side effects_____________________________________
Number adults on 1st line regimen with pill count done in last month of quarter
Number with the pill count in the last month of the quarter at 8 or less___________

Of those who died: Number in month 1______ Number in month 2______
Number in Month 3______ Number after month 3______
36-month survival: outcomes by end of December 2007

New patients registered for ART between October and December 2004: __________

Number Alive and on ART ________________________________

Number Dead ________________________________

Number Defaulted ________________________________

Number Stopped Treatment ________________________________

Number Transferred Out ________________________________

24-month survival: outcomes by end of December 2007

New patients registered for ART between October and December 2005: __________

Number Alive and on ART ________________________________

Number Dead ________________________________

Number Defaulted ________________________________

Number Stopped Treatment ________________________________

Number Transferred Out ________________________________

12-month survival: outcomes by end of December 2007

New patients registered for ART between October and December 2006: __________

Number Alive and on ART ________________________________

Number Dead ________________________________

Number Defaulted ________________________________

Number Stopped Treatment ________________________________

Number Transferred Out ________________________________

Number of HIV-related diseases diagnosed in quarter: Specify ________
TB patients registered in TB Register______________________________

Kaposi’s Sarcoma patients__________________________________________

Cryptococcal meningitis patients in Diflucan Register_________________

Oesophageal candida patients in Diflucan Register____________________

Number of persons given post-exposure prophylaxis in the quarter:________

CPT:

Has your site ever provided CPT to ART patients: YES_______ NO________

If YES,

Has the site provided CPT to: 100% of patients____

50% of patients____

25% of patients____

Post Exposure Prophylaxis (PEP)
Number of persons provided PEP for occupational injuries:
Number of persons provided PEP for rape/sexual assault: